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ABSTRACT 
Neuropathy is one of the many health consequences of long-term excessive alcohol 
consumption. To date, no effective treatment is available for alcoholic neuropathy and its 
pathogenesis remains unknown. Animal studies have proposed potential mechanisms 
underlying the association between alcohol abuse and pain conditions. Specifically, 
preclinical studies have demonstrated that exposure to a few cycles of alcohol withdrawal 
sensitizes pain pathways and that the two major stress hormones (i.e., epinephrine and 
cortisol) mediate the induction and maintenance of alcohol withdrawal-induced 
hyperalgesia. The current study was designed to determine the generality of this 
phenomenon and mechanisms of alcohol withdrawal-induced hyperalgesia in humans. 
Because alcohol withdrawal-induced hyperalgesia occurs after only four cycles of an 
ethanol binge diet in rats, the first objective of the current study was to determine whether 
alcohol withdrawal-induced hyperalgesia would occur in young adult binge drinkers with 
a relatively short history of drinking. The second objective was to determine whether stress 
hormones would be associated with this hyperalgesia. The third goal was to examine the 
role of negative affect in alcohol withdrawal-induced hyperalgesia because it is a common 
withdrawal symptom and is linked to enhanced physiological stress responses and pain 
sensitivity in humans. The last goal was to examine whether alcohol withdrawal and pain 
would enhance alcohol craving, and therefore, have the ability to motivate continued 
drinking. To achieve these objectives, two experiments were conducted. Experiment 1 was 
a cross-sectional design examining the effect of naturally occurring drinking episodes. 
Experiment 2 was a within-subject design with laboratory alcohol administration. The 
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current study translated two of the animal findings to humans. First, binge drinkers showed 
hypersensitivity to muscle pressure pain and alcohol withdrawal further enhanced this 
hyperalgesia. Second, binge drinkers showed elevated basal levels of epinephrine, but 
withdrawal did not further increase epinephrine. All the other results were negative. In 
sum, the current results indicate that alcohol withdrawal-induced hyperalgesia occurs in 
young adult binge drinkers with a relatively short history of binge drinking and even 
before the development of alcoholic neuropathy. The study also suggests epinephrine may 
play a role in alcohol withdrawal-induced hyperalgesia. 
  
 iv 
ACKNOWLEDGEMENTS 
I would like to thank my committee chair, Dr. Meagher, and my committee 
members, Dr. Grau, Dr. Tassinary, and Dr. Fields, for their guidance and support 
throughout the course of this research. Additionally, I thank Dr. Thomas H. Welsh for his 
training in analyzing and interpreting an enzyme-linked immunosorbent assay.  
Thanks also go to my undergraduate research assistants, laboratory technicians, 
and laboratory colleagues for their contribution to this research project. I also want to 
extend my gratitude to the National Institute on Alcohol Abuse and Alcoholism, and the 
Texas A&M University College of Liberal Arts, for providing financial support for my 
graduate study and this research project.  
Finally, thanks to my family for their encouragement, patience, and love. 
  
 v 
CONTRIBUTORS AND FUNDING SOURCES 
Contributors 
This work was supervised by a dissertation committee consisting of committee 
chair, Professor Mary Meagher, of the Department of Psychology and Institute for 
Neuroscience (the student’s advisor), Professors James W. Grau and Sherecce Fields (also 
of the Department of Psychology and Institute for Neuroscience), and Professor Louis 
Tassinary, of the Department of Visualization, College of Architecture.  
Funding Sources 
Graduate study was supported by an NRSA Predoctoral Fellowship from the 
National Institute on Alcohol Abuse and Alcoholism (NIAAA). This work was made 
possible in part by the Dissertation Enhancement Award from the College of Liberal Arts, 
Texas A&M University.  
 
 vi 
TABLE OF CONTENTS 
 Page 
ABSTRACT……………………………………………..………………………... ii 
ACKNOWLEDGEMENTS………………………………………………………. iv 
CONTRIBUTORS AND FUNDING SOURCES………………………………… v 
TABLE OF CONTENTS…………………………………………………………. vi 
LIST OF FIGURES……………………………………………………………….. viii 
LIST OF TABLES………………………………………………………………... xi 
1 INTRODUCTION………………………………………………………….. 1 
2 EXPERIMENT 1…………………………………………………………… 14 
3 METHODS EXPERIMENT 1………………………………..…………….. 17 
 3.1 Measures…………..……………………………………………………. 
3.2 Procedures……………..…...…………………………………………… 
3.3 Statistical Analysis………..…………………………………………….. 
17 
26 
28 
4 RESULTS EXPERIMENT 1……………..………………………………… 32 
 4.1 Psychological Traits…………………..……………......……………….. 
4.2 Baseline Psychological and Physiological States……...…......…………. 
4.3 Pain Sensitivity…………………..…………………….………………... 
4.4 The Role of Stress Hormones in Pain Sensitivity..……………………… 
4.5 The Role of Negative Affect in Pain Sensitivity..……………………….. 
4.6 Psychological Responses to Pain Testing………..……………………… 
4.7 Physiological Responses to Pain Testing………..……………………… 
33 
36 
37 
38 
42 
43 
44 
5 EXPERIMENT 2…………………………………………………………… 47 
6 METHODS EXPERIMENT 2...……………………………………………. 51 
 6.1 Measures..………………………………………………………………. 
6.2 Procedures..…………………………………………………...………… 
6.3 Statistical Analysis……………………………………………………… 
51 
57 
60 
7 RESULTS EXPERIMENT 2...……………………………………………... 61 
 7.1 Psychological Traits…………………………………………………….. 63 
 vii 
7.2 Baseline Psychological and Physiological States……..………………… 
7.3 Influence of Alcohol on Visit 3………………..………………………... 
7.4 Pain Sensitivity………………………………………………………….. 
7.5 The Role of Stress Hormones in Pain Sensitivity……………………….. 
7.6 The Role of Negative Affect in Pain Sensitivity………………………… 
7.7 Psychological Responses to Pain Testing……………………………….. 
7.8 Physiological Responses to Pain Testing……………………………….. 
7.9 The Role of Alcohol Withdrawal and Pain in Alcohol Craving………… 
64 
65 
65 
75 
78 
79 
81 
83 
8 DISCUSSION………………………………………………………………. 85 
9 REFERENCES……………………………………………………………... 97 
 viii 
LIST OF FIGURES 
Figure Page 
1 Timeline of alcohol withdrawal symptoms…...……………………………... 5 
2 Becker (1998)’s graphical presentation of kindling process, modified 
(Reprinted, public domain document)…………………………………......... 8 
3 Egli et al. (2012)’s schematic diagram describing the bi-directional 
relationship between alcohol use and chronic pain (Reprinted, public 
domain document)………………………………………………..…..……... 9 
4 Koob and Le Moal (2008)’s hypothetical diagram illustrating sources of 
vulnerability in addiction (Reprinted with permission by the authors)……... 11 
5 Prevalence of different drinking patterns in young adults…………………... 15 
6 L5 dermatome……………………………………………………………….. 20 
7 Von Frey application...………………………………………………………. 21 
8 Thermode application……………………………………………………….. 22 
9 Algometer application……..….……………………………………………... 23 
10 Experiment 1 timeline……………………………………………………...... 28 
11 Comparison of mechanical, heat, and pressure pain thresholds between the 
groups with different drinking patterns……………………………………… 38 
12 Comparison of baseline epinephrine levels and their responses to pain 
between the groups with different drinking patterns………………………... 39 
13 Comparison of baseline cortisol levels and their responses to pain between 
the groups with different drinking patterns………………………………….. 41 
14 Pearson correlations between baseline STAI scores and PPT were compared 
across the groups with different drinking patterns…………………………... 42 
15 Changes in the SAM-valence, arousal, and dominance in response to pain 
tests…………………………………………………………………………... 43 
 ix 
Figure Page 
16 Changes in HR, SCL, and RR before, during, and after pain testing……….. 44 
17 Experiment 1 prevalence of different drinking patterns in young adults……. 48 
18 The grids on the pain testing sites (left) and electronic von Frey application 
(right)………………………………………………………………………… 53 
19 Capsaicin application on a filter paper………………………………………. 54 
20 Laser Doppler imaging to measure flare in a supine position…...…………... 56 
21 Experiment 2 timeline….………………………………………..…………... 58 
22 Changes in mechanical, heat, and pressure pain threshold from Visit 1 to 
Visit 3………………………………………………………………………... 66 
23 Average pain intensity and unpleasantness ratings every two minute on 
Visit 1 and Visit 3…………………………………………………………… 67 
24 Scatter plots for each individual’s average capsaicin-induced pain intensity 
(top left) and unpleasantness (top right) on Visit 1 and changes in pain 
intensity (bottom left) and unpleasantness (bottom right) on Visit 3……….. 68 
25 Scatter plots for each individual’s peak pain intensity (top left) and 
unpleasantness (top right) during capsaicin application on Visit 1. Scatter 
plots for change in pain intensity (bottom left) and unpleasantness (bottom 
right) on Visit 3…………………………………...…………………………. 69 
26 Predicting capsaicin induced-peak pain intensity from the number of drinks 
during weekends…………………………………………………………….. 70 
27 Comparison of flare size on Visit 1 and changes in flare size on Visit 3…… 71 
28 Graphical depiction of the areas of secondary allodynia on the capsaicin 
application site using two methods for Visit 1 and Visit 3………………….. 72 
29 Pain intensity ratings to 26g von Frey on non-dominant foot before 
capsaicin application………………………………………………………… 74 
   
 x 
Figure Page 
30 Changes in epinephrine levels before and after pain testing on Visit 1 (top 
left) and Visit 3 (top right), and comparison of overall epinephrine levels 
between the groups (bottom)………………………………………………… 76 
31 Changes in cortisol levels before and after pain testing on Visit 1 (top left) 
and Visit 3 (top right), and comparison of overall cortisol levels between 
the groups (bottom)………..………………………………………………… 77 
32 Changes in the SAM-valence, arousal, and dominance in response to pain 
tests on Visit 1 (left) and Visit 3 (right)……………………………………... 80 
33 Changes in HR, SCL, and RR before, during, and after pain testing on Visit 
1 and Visit 3…………………………………………………………………. 82 
34. Changes in ACQ scores before and after pain testing on Visit 1 and Visit 3.. 84 
 
 xi 
LIST OF TABLES 
Table Page 
1 Experiment 1 Demographics and drinking patterns……………………......... 32 
2 Experiment 1 Psychological traits…………………………………………… 34 
3 Experiment 1 Baseline psychological and physiological states……………... 36 
4 Experiment 2 Demographics and drinking patterns………………………..... 61 
5 Experiment 2 Psychological traits………...…………………………………. 62 
6 Experiment 2 Baseline physiological and psychological states……………... 64 
 
 
 
 
 
 
 1 
1. INTRODUCTION 
Alcohol is the most widely used substance. According to a 2014 national survey, 
about half of Americans aged 12+ drink alcohol (1). This survey also reveals that binge 
(23%) and heavy drinking (6%) are common. Across different age groups, binge drinking 
is much more common for young adults (38%) compared to adolescents (6%) and adults 
(23%) (1). The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines 
binge drinking as 4(women)/5(men) drinks in about 2 hours. This pattern of drinking, a 
large amount of alcohol in a short time, brings blood alcohol concentration (BAC) levels 
to at least 0.08%. Heavy drinking is defined as 5+ drinks on an occasion at least one day 
in the past 30 days. Excessive drinking in the form of binge or heavy drinking leads to 
many physical and mental health problems (2). Painful neuropathy is one of the health 
problems after long-term excessive use, but can develop for some after a relatively short 
period of alcohol abuse: 20% in the first 5 years and 40% after 10 years of alcohol abuse 
(3). The pathogenesis of alcohol-induced painful neuropathy is largely unknown and no 
effective treatment is currently available. Therefore, systematic investigation of its 
mechanisms is a critical first step toward designing more effective treatment approaches.  
Studies examining the relationship between alcohol and pain have found that 
alcohol has both analgesic and hyperalgesic properties. Alcohol’s analgesic property has 
been well established in humans. Wolff and colleagues have systematically examined the 
analgesic effect of alcohol in the 1940s, demonstrating that drinking 15 to 90cc of 95% of 
alcohol quickly raises heat pain threshold within 10 minutes (4). The peak analgesic 
effects occur within 40 minutes for small amounts of alcohol (70cc) and 15 minutes for 
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the larger amounts (90 cc). The maximum analgesic effect is a 45% increase in heat pain 
threshold with 30cc of 95% alcohol and there are no further analgesic effects with 
additional amount of alcohol (i.e., 40-90cc). The analgesic effect from a large amount of 
alcohol disappears within 4 hours and therefore, it is considered a short-term analgesic 
(4). Some argue that alcohol produces inadequate antinociceptive effects to be a useful 
analgesia, but it is effective in reversing withdrawal-induced hyperalgesia (5). This 
reversal suggests alcohol may be a negative reinforcer for continuous drinking.  
Although alcohol’s hyperalgesic properties have not received much attention in 
human studies, alcohol withdrawal-induced hyperalgesia is a well-established 
phenomenon in animal models of binge drinking. After one cycle of an ethanol binge diet 
(4 days on/3days off), rats develop hyperalgesia to pressure pain on the dorsum of the hind 
paw during ethanol withdrawal (6). This hyperalgesia worsens with repeated cycles of an 
ethanol binge diet up to 4 weeks and persists up to 5 weeks at the time of study termination. 
More importantly, this study has shown the critical role of withdrawal in the development 
of hyperalgesia (6). Contrary to ethanol-binge diets, a continuous ethanol diet (7days on/0 
days off) reduces pain threshold much later (i.e., after 4 cycles) to a small degree. 
Additionally, switching to a continuous ethanol diet (7days on/0 days off) after one cycle 
of an ethanol binge diet (4 days on/3days off) does not further decrease pain threshold. 
This suggests that repeated alcohol withdrawals, not excessive use of alcohol, contribute 
to the development of and further worsening of hyperalgesia. Furthermore, fewer days on 
an ethanol diet (1, 2, or 3 days on/3 days off) produce rapid and greater hyperalgesic 
effects than more days on an ethanol diet (4 days on/3days off). This indicates that 
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consuming alcohol for more consecutive days does not contribute to hyperalgesia, but 
rather produces a protective effect. This protective effect of alcohol possibly motivates 
continued drinking despite multiple physical and psychosocial problems that result from 
excessive drinking.  
A human study has also shown evidence for alcohol withdrawal-induced 
hyperalgesia (7). Middle-aged men with alcohol dependence, but without other physical 
problems (e.g., diabetes, liver cirrhosis, and peripheral neuropathy) show reduced heat 
pain thresholds and tolerances on the left volar wrist and sternum during hospitalization 
for acute alcohol detoxification (7). This hyperalgesia is reversible with alcohol 
abstinence. This human study indicates that alcohol withdrawal-induced hyperalgesia can 
occur in those with alcohol dependence even before the occurrence of alcoholic 
neuropathy. However, it remains unclear whether alcohol withdrawal can induce 
hyperalgesia in those who have a relatively short history of binge drinking and even before 
the development of alcohol dependence.  
Changes of pain sensitivity occur during two phases: acute and chronic. The acute 
phase refers to changes in pain sensitivity during acute alcohol withdrawal, and the chronic 
phase refers to persistent changes in the absence of alcohol consumption. For the acute 
phase, the time of the withdrawal-induced hyperalgesia seems to vary depending on 
testing method (pain modality) and drinking patterns. According to an animal study, heat 
hyperalgesia on the tail flick tests emerges at 3 hours, peaks between 6 and 12 hours, and 
disappears within 36 hours after stopping a 10-day ethanol diet (8). Another animal study 
shows inflammatory hyperalgesia on the formalin test at 12 hours after stopping a 10-day 
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ethanol diet (9) and heat hyperalgesia on the tail flick and hot plate tests at 24 hours after 
stopping a 7-day of ethanol diet. Unlike the former study with tail-flick test (8), the latter 
studies have not explored the time course of the development of withdrawal-induced 
hyperalgesia. Compared to withdrawal after a consecutive ethanol diet for 7 or 10 days, 
withdrawal after an ethanol binge diet (4 days on/3 days off) produces more persistent 
hyperalgesia in paw-pressure tests (6). Specifically, hyperalgesia is observed at 12 hours, 
peaks at 60 hours, and lasts for 7 days after stopping the ethanol diet (6). The time course 
of hyperalgesia during alcohol withdrawal in humans is unknown, but the symptoms of 
alcohol withdrawal have been well characterized. Therefore, the withdrawal symptoms 
will be reviewed next to estimate the potential time window for alcohol withdrawal-
induced hyperalgesia.  
DSM-5 diagnostic criteria for alcohol withdrawal syndromes are two or more of 
the following symptoms within several hours to a few days after cessation or reduction of 
alcohol use. Such symptoms are a) insomnia, b) autonomic hyperactivity (e.g., sweating 
or heart rate > 100 bests/min), c) increased hand tremor, d) nausea or vomiting, e) 
psychomotor agitation (physical restlessness), f) anxiety, g) hallucinations or perceptual 
disturbances of the auditory, tactile, or visual type, and h) grand mal seizure (10). Minor 
withdrawal symptoms generally occur within 6 to 12 hours after the drinking episode, 
followed by hallucination (12-24 hours), withdrawal seizures (24-48 hours), and delirium 
tremens (48-72 hours), summary in Fig. 1 (11). 
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Fig. 1. Timeline of alcohol withdrawal symptoms 
 
 
 
In the early stages of binge drinking, withdrawal symptoms are commonly called 
hangover symptoms. A study examining hangover symptoms after naturalistic drinking at 
a Danish beach has shown that hangover symptoms occurred in 68% of 112 young adults 
after drinking at least 12 standard drinks and that symptom severity is dose-dependent and 
increases over time with repetitive alcohol consumptions (12). An alcohol administration 
study in Sweden shows a similar finding. Of 172 adults who drank alcohol to 0.10% BAC 
(7:30pm - 10pm), 76% reported hangovers on the following morning at 8am (13). The 
most common symptoms were thirst (100%), tiredness (98%), headaches (66%), 
dizziness/faintness (50%), loss of appetite (45%), stomachache (26%), nausea (25%), and 
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heart racing (18%), but emotional states and typical drinking patterns were not evaluated 
in this study (13). Others have observed elevated anxiety symptoms in the morning after 
drinking 3.25ml/kg body weight of bourbon or vodka from 8pm to midnight (14). In this 
study, the BAC was on average 0.093% immediately after drinking and at minimal levels 
(0.005% for bourbon and 0.007% for vodka) on the following morning, 8 hours after 
drinking. Alcohol withdrawal and hangover symptoms are similar in that headaches, 
fatigue, and poor sense of overall well-being are common in both conditions, but are 
dissimilar in that hallucinations and seizures are uncommon in hangover (15,16). 
Additionally, the duration of hangovers is shorter whereas withdrawal symptoms last up 
to 5 days after drinking (16). Across these different studies, hangover symptoms are 
evaluated within 24 hours after drinking and hyperalgesia may occur within this 
timeframe.  
In addition to the time course, the mechanisms of alcohol withdrawal-induced 
hyperalgesia are understudied in humans. In an animal model of ethanol binge diets, Dina 
and colleagues have found two stress hormones as the mediators of withdrawal-induced 
hyperalgesia (17). Their data show that an ethanol binge diet increases plasma epinephrine 
levels about 1.8 times by the third week and the level is further elevated about 1.9 times 
during alcohol withdrawal, 18 hours after the ethanol diet (17). This elevated epinephrine 
plays a critical role in the induction and maintenance of the hyperalgesia. Blocking 
epinephrine by adrenalectomy prevents the occurrence of alcohol withdrawal-induced 
hyperalgesia and reverses the established hyperalgesia despite the continuation of the 
ethanol binge diet (17). Then, a constant infusion of epinephrine reinstates the 
 7 
hyperalgesia within a week (17). Plasma cortisol also plays a similar role. Administration 
of a glucocorticoid receptor antagonist prevents and reverses the withdrawal-induced 
hyperalgesia (17). These results suggest the involvement of the sympatho-adrenal 
medullary (SAM) and hypothalamo-pituitary-adrenal (HPA) stress axes in the induction 
and maintenance of the hyperalgesia.  
A review of animal findings explains other potential mechanisms involved in the 
induction of withdrawal-induced hyperalgesia: GABAA, calcium channels, adenosine 
receptors, analgesics, NMDA and other glutamate receptors, and signal transduction 
pathways (5). GABAA antagonists, calcium channel blockers, and adenosine antagonists 
prevent or attenuate the development of ethanol-withdrawal hyperalgesia, but they do not 
reverse the hyperalgesia. COX-2 selective NSAIDs also prevent ethanol withdrawal-
hyperalgesia, but reversal has not been investigated. Although not being tested in intact 
animals, ethanol withdrawal-induced hyper-excitability of NMDA receptors has been 
observed in the spinal cord (5). Lastly, protein kinase C epsilon (PKCε) is involved in the 
induction and maintenance of withdrawal-induced hyperalgesia (6,18). PKCε, a cellular 
signaling pathway, is known to play an important role in mechanical hyperalgesia in 
models of inflammatory, neuropathic and generalized widespread pain (19). Levels of 
expression of PKCε in the dorsal root ganglia are increased by 50% after a chronic ethanol 
diet (18). Intrathecal injection of an antisense oligonucleotide against PKCε reduces 
hyperalgesia in the induction and maintenance phase (6). Consequently, the PKCε 
signaling pathway and the above-mentioned mechanisms are possibly involved in alcohol 
withdrawal-induced hyperalgesia in humans. To date, studies have focused on the 
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peripheral and spinal cord mechanisms and little is known about the supra-spinal 
mechanisms. 
 
 
 
Fig. 2. Becker (1998)’s graphical presentation of kindling process, modified  
(Reprinted, public domain document) 
 
 
 
Alcohol suppresses the central nervous system (CNS) functions. When alcohol 
levels decline during withdrawal, the CNS hyperexcitability occurs as a compensatory 
response (20). This CNS hyperexcitability manifests as withdrawal symptoms of tremors, 
agitation, seizures, and delirium tremens (20). Although these withdrawal symptoms are 
not common in early stages of binge drinking, repeated alcohol withdrawal episodes 
sensitize people to subsequent withdrawal episodes and withdrawal symptoms worsen 
over time. Kindling may explain increased neuronal excitability with repeated alcohol 
withdrawal episodes, Fig. 2 (20). Withdrawal-induced brain function changes are 
characterized by imbalance of inhibitory/excitatory neurotransmission (↓ GABAA 
 9 
receptor, altered adenosine, ↑ NMDA receptor, ↑ voltage-gated C channel functions), 
neuroendocrine dysregulation (↑ HPA axis activation), and other neurochemical 
perturbations (↓ dopamine function) (20). As a result of kindling, seizure susceptibility, 
anxiety, and neurotoxicity are increased and the subjective perception of alcohol effect 
changes over time.  
 
 
 
Fig. 3. Egli et al. (2012)’s schematic diagram describing the bi-directional relationship 
between alcohol use and chronic pain. (Reprinted, public domain document) 
 
 
 
Alcohol’s immediate analgesic effect and the delayed onset of the hyperalgesic 
effect during withdrawal create a vulnerability to alcohol dependence, Fig. 3 (21). The 
immediate reward of an analgesic effect can motivate drinking. Here, alcohol is a positive 
reinforcer. Following opposing dysphoric and hyperalgesic acute withdrawal states can 
also motivate drinking to reduce emotional distress and pain. In this case, alcohol is a 
negative reinforcer. Because withdrawal symptoms are intensified with repeated binge 
drinking, alcohol’s negative reinforcing effect becomes more critical in continued 
 10 
drinking. Especially, persistent negative affect and hypersensitivity to emotional distress 
(hyperkatifeia) during withdrawal become strong motives for drinking in alcoholics (21).  
Egli and colleagues suggest that alcohol dependence is a chronic pain disorder 
because affective (hyperkatifeia) and sensory components of pain (hyperalgesia) could 
promote excessive drinking (21). Additionally, the dysregulated reward and emotional 
neural circuits found in chronic pain conditions and alcohol dependence could alter central 
pain processing and alcohol drinking patterns (22). Specifically, the dysregulated reward 
system involves increased connectivity between nucleus accumbens and medial prefrontal 
cortex (mPFC), indicating over-activation of the brain reward system. Dysregulation of 
the emotional neural circuit leads to increased activity in the amygdala and impaired 
function of the mPFC, which are associated with more negative affect and less top-down 
cognitive control of pain and alcohol use.  
Persistent pain and repeated episodes of excessive alcohol intoxication and 
withdrawal can also alter the brain stress circuit (signaling corticotropin-releasing factor 
[CRF] in the central nucleus of the amygdala) (22). Koob and Le Moal introduce a concept 
of anti-reward system to explain the transition from substance use to abuse or dependence. 
To oppose the over-activation of the brain reward system from binge drinking, the anti-
reward system (i.e., the brain stress system) is recruited as part of a neuroadaptation 
process (23). Consequently, the combination of a reduced reward system (decreased 
dopamine and euphoria) and an enhanced anti-reward system (increased CRF and 
increased dysphoria and distress) produces a powerful motivational state for addiction. 
Eventually, this dysregulation of the motivation systems results in a switch from impulsive 
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substance use to compulsive use (Fig. 4). Under the influence the anti-reward system, 
stress and negative affect not only can promote drinking, but also can produce pain 
hypersensitivity (22).  
 
 
 
Fig. 4. Koob and Le Moal (2008)’s hypothetical diagram illustrating sources of 
vulnerability in addiction (Reprinted with permission by the authors) 
 
 
 
This review of the literature suggests that excessive drinking and pain influence 
each other and identifies several mechanisms that are proposed to be tested in humans. As 
an initial effort to unravel this complex relationship, the current study focused on the effect 
of alcohol-withdrawal on pain sensitivity, the role of stress hormones and negative affect 
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in withdrawal-induced hyperalgesia, and pain as a potential motivational force for 
drinking. Specific objectives were as follows. The first objective was to examine whether 
alcohol withdrawal induced hyperalgesia would occur in young adult binge drinkers who 
would have a relatively short history of binge drinking and therefore would have relatively 
less episodes of alcohol withdrawal. The second objective was to examine whether stress 
hormones (i.e., epinephrine and cortisol) would be correlated with drinking patterns. 
Third, this study examined whether negative affect (i.e., anxiety) would enhance alcohol 
withdrawal-induced hyperalgesia. Finally, this study examined whether pain and alcohol-
withdrawal would enhance alcohol craving and therefore potentially motivate drinking. 
To achieve these objectives, two experiments were conducted. Experiment 1 was a cross-
sectional study examining peripheral pain sensitivity after naturally occurring alcohol use. 
Experiment 2 was a within-subject design examining capsaicin-induced pain sensitivity 
with laboratory alcohol administration. Capsaicin was used in Experiment 2 to examine 
various characteristics of inflammatory-mediated pain processing (24). Capsaicin is an 
active ingredient of hot chili pepper and selectively activates transient receptor potential 
vanilloid 1, which locally releases various pro-inflammatory neuropeptides such as 
substance P and calcitonin gene-related peptide (24). Consequently, topical capsaicin 
temporarily induces spontaneous burning pain on the capsaicin application site, flare, and 
primary and secondary hyperalgesia. Primary hyperalgesia is enhanced pain sensitivity on 
the affected site and secondary hyperalgesia is enhanced pain sensitivity on the adjacent 
unaffected sites. Different from the other pain measures, the results of secondary 
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hyperalgesia as a proxy measure for central sensitization would inform whether alcohol 
withdrawal would alter central pain processing (25,26).  
It was hypothesized that binge drinkers would show pain hypersensitivity and this 
hypersensitivity would be further enhanced during acute alcohol withdrawal. 
Additionally, it was hypothesized that stress hormones would be increased in binge 
drinkers and be further amplified during acute alcohol withdrawal; that more negative 
affect during alcohol withdrawal would be associated with enhanced hyperalgesia; and 
that alcohol withdrawal and pain during alcohol withdrawal would increase craving.  
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2. EXPERIMENT 1 
Texas A&M University Institutional Review Board approved the study procedures 
and informed consent was obtained from all participants. Participants were recruited from 
the Summer 2014 to the Fall 2015. Participants were eligible for inclusion if they were 
healthy young adults between 18 and 30 years old. Exclusion criteria were any chronic 
health issues including chronic pain, prescription medication use (except contraceptives), 
history of vasovagal syncope, and needle phobia.  
Potential participants completed an online prescreening survey (Qualtrics.com) 
evaluating health status and drinking history. Typical drinking patterns were assessed by 
a statement, “Select one that describes your alcohol drinking,” with options never, former, 
and current drinker. Those who endorsed “Never” (57%) were classified as abstainers. 
Those who endorsed as “former” drinkers (6%) were not invited. Those who endorsed 
being “current” drinkers (37%) were asked to complete the Daily Drinking Questionnaires 
(DDQ) (27). On the DDQ, participants were asked to report the number of standard drinks 
and hours spent drinking for a typical and heaviest drinking week in the last 30 days. Those 
who endorsed as current drinkers, but reported no alcohol use in the past 30 days were not 
invited. Individuals who reported their maximum alcohol consumption less than 
4(women)/ 5(men) standard drinks per episode were invited as moderate drinkers. 
Individuals who reported their typical alcohol consumption as at least 4(women)/ 5(men) 
standard drinks for 2 hours were invited as binge drinkers. Heavy, but not binge, drinkers 
defined by at least 4 (women)/5 (men) standard drinks over more than 2 hours were not 
invited.  
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Fig. 5. Prevalence of different drinking patterns in young adults 
 
 
 
Of the total 1,562 women and 664 men who completed the prescreening (Mage = 
19.4, SDage = 2.1, 18-30 years), 13% were abstainers, 12% were binge drinkers, and 
another 12% were heavy drinkers regardless of eligibility criteria (Fig. 5). About a third 
(29%) were not invited due to meeting ineligibility criteria.  
Of the total 1,573 eligible participants who were invited via email, 177 people 
participated in this study and all consented participants completed the laboratory 
experiment. Prior to the laboratory visit, scheduled individuals were instructed not to take 
pain or allergy medicine 3 days before the experiment and not to drink caffeine or to 
exercise vigorously 4 hours before the experiment. Participants were instructed to 
reschedule the visit if they had an injury or skin condition on the feet (QST testing site) or 
acute illness on the day of the experiment. Compliance to these study preparations was 
verbally verified at the beginning of the experiment. In case of non-compliance, the 
experiment was rescheduled. Participants’ drinking patterns were assessed again in the 
 16 
laboratory after the sensory testing and actual drinking patterns were modified as 
necessary. Most participants (85%) received class credit for their participation and the rest 
participated to be entered in a raffle to win one of the three $100 gift cards.  
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3. METHODS 
EXPERIMENT 1 
3.1 Measures 
The following measures were administered to characterize binge drinkers’ 
psychological traits as well as to examine the roles of negative affect in alcohol-
withdrawal induced hyperalgesia.  
Self-reports 
The Perceived Stress Scale (PSS) is a 10-item measure used to assess levels of 
perceived life stress in the last month (Cronbach’s α =.78) (28). The scale ranges from 0: 
Never to 4: Very Often. Of the 10 items, four items are reversed coded. The total scores 
range from 0 to 40 with higher scores indicating higher levels of perceived stress. This 
scale has been validated in college students as well as in the general population (28). The 
reported norms for young adults is 14.2 with SD of 6.2. The average PSS score of the 
current sample was 16.6 (SD = 6.0), which was higher than previously observed norm (t 
= 4.59, p < .001). 
The Depression Anxiety Stress Scales (DASS) is a 21-item questionnaire to 
assess the symptom severity of depression (Cronbach’s α =.94), anxiety (Cronbach’s α 
=.87), and life stress (Cronbach’s α =.91) over the past week for a community sample (29). 
This measure uses a 4-point Likert scale, ranging from 0: Did not apply to me at all 
(Never) to 3: Applied to me very much, or most of the time (Almost Always). Seven items 
were used to evaluate each symptom domain. The severity of each symptom is calculated 
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by multiplying the summed scores by 2. Therefore, the total scores range from 0-42. 
Reported normal ranges are less than 10 for depressive symptoms, less than 8 for anxiety 
symptoms, and less than 15 for stress (30). The respective averages scores of DASS-
depression, anxiety, and stress of the current sample were 5.6 (SD = 6.3), 4.7 (SD = 4.7), 
and 9.2 (SD = 6.4). Therefore, our participants’ symptoms were all on average within the 
normal limits. 
The Alcohol Craving Questionnaire (ACQ-NOW)-short form is a self-report 
questionnaire used to assess levels of alcohol craving. Of the 12 items, 8 items were 
reversed coded before summing up to compute the levels of craving. The items are scored 
on a 1: strongly disagree to 7: strongly agree scale. This measure evaluates four 
dimensions, with each dimension having 3 items: emotionality (negative emotional state, 
Cronbach’s α =.86), purposefulness (desire and intent to drink right now, Cronbach’s α 
=.77), compulsivity (lack of confidence in ability to quit drinking, Cronbach’s α =.79), 
and expectancy (positive alcohol expectancy, Cronbach’s α =.77) (31).  
The Barratt Impulsiveness Scale (BIS-11) is a self-report measure to assess 
levels of impulsivity (Cronbach’s α =.82 for undergraduates) (32). The scale is composed 
of 30 items (10 revered coded items) and each item is scored on a 4-point scale from 1: 
Rarely/Never to 4: Almost always/Always. The total scores range from 30 to 120 with 
higher scores indicating greater impulsivity. Additionally, the BIS-11 has three subscale 
scores: inattention (8 items), motor restlessness (11 items), and non-planning (11 items).  
The Hangover Symptoms Scale (HSS) is a 5-point, self-report to assess the 
frequency of 13 hangover symptoms over the past 12 months (33). The scale ranges from 
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0 (0% of the time) to 4 (100% of the time). The items were dichotomized to identify 
presence (1 = 1 – 4) or absence (0 = 0) of the symptom and then, summed. Therefore, the 
possible total scores range from 0 to 13, with higher scores indicating more hangover 
symptoms (Cronbach’s α =.83 for men and .84 for women) (33). This measure was 
administered in the prescreening questionnaire to evaluate typical hangover symptoms and 
to compare acute hangover symptoms after the laboratory pain testing.  
The Acute Hangover Scale (AHS) is a self-report measure used to assess acute 
hangover symptoms (Cronbach’s α = .84) (34). The 9 items of hangover symptoms, 
thirsty, tired, headache, dizziness, loss of appetite, stomachache, nausea, and heart racing 
are rated on a 0: None to 7: Incapacitating scale. The average AHS total scores are 1.4 
(SD = 0.9) on the morning after alcohol intoxication and 0.6 (SD = 0.4) on the morning 
after placebo (34).  
The following measures were administered to evaluate emotional responses to pain 
testing. 
The Spielberger State-Trait Anxiety Inventory-6 (STAI) is a 6-item measure 
used to evaluate levels of state anxiety (Cronbach’s α =.82) (35). The items are scored on 
a 4-point scale; 1 Not at all to 4: Very much. The total scores range from 6 to 24 with 
higher scores indicating higher levels of anxiety.  
The Self-Assessment Manikin (SAM) is a 9-point scale pictogram measuring 
affective dimensions of valence, arousal, and dominance (36). The valence scale ranges 
from 1: Happy to 9: Unhappy, the arousal scale ranges from 1: Calm to 9: Excited, and the 
dominance scale ranges from 1: Feeling being controlled to 9: Feeling in control.  
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The Positive and Negative Affect Schedule (PANAS) is used to evaluate two 
dimensions of current mood such as positive and negative affective states (37). The 
PANAS consists of two 10-items for positive (PA) and negative affect (NA). The possible 
total scores are between 10 and 50 for positive (Cronbach’s α = .85) and negative affect 
(Cronbach’s α = .89) (37). Higher scores indicate more positive or negative affect.  
Quantitative Sensory Testing (QST) 
All pain testing was conducted in a sound-attenuated and temperature controlled 
room (20-25 ºC). Because alcohol-induced polyneuropathy often affects the nerves in legs 
or feet (38,39), pain testing was conducted on the dorsum of the non-dominant foot (L5 
dermatome, Fig. 6). Non-dominant foot was identified by asking a question, “which foot 
do you use to kick a ball?” If response was unknown or equal, the foot with a smaller 
circumference of the calf muscle was considered to be non-dominant. A modified 
Quantitative Sensory Testing (QST) protocol of the German Research Network on 
Neuropathic Pain was used to measure mechanical, heat, and pressure pain thresholds 
(40). The details of the QST protocol are described below. 
 
 
Fig. 6. L5 dermatome 
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Fig. 7. Von Frey application 
 
 
 
The mechanical pain threshold was measured using the method of limits (40). 
Fixed stimuli with a set of seven Von Frey filaments (0.6, 1.4, 4, 6, 15, 26, and 60gF, 
Stoelting Co. Wood Dale, IL, USA) were applied at a rate of 2s on and 2s off in an 
ascending order until participants first perceived a von Frey stimulus as being painful. 
Then, filaments were applied in a descending order until the first perception of no pain 
was reported. Von Frey is a calibrated monofilament that bends at a certain pressure. An 
experimenter puts a von Frey filament on a skin at a 90º angle and slowly increases the 
pressure until it bends (Fig. 7). To void sensory fatigue and local sensitization, a von Frey 
filament was applied to a different location and the time interval between one trial and 
another was at least 10s. The mechanical pain threshold on feet (using a 0.2 diameter von 
Frey) is reported to be on average 9.0gF (SD = 7.6) (41).  
The Geometric mean of the three series of ascending and descending stimulus 
intensity was used to calculate individual mechanical pain threshold. When some 
participants reported no painful sensation with the highest force (60gF), the next available 
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highest force (100gF) was used as their pain threshold. The German protocol uses a 
customized von-Frey with a diameter of 0.2mm whereas the diameters of the 
commercially available von Frey (Stoelting Co.) vary across different forces. Specifically, 
respective diameters of the seven von Frey filaments were 0.20, 0.25, 0.36, 0.38, 0.48, 
0.56, and 0.71 mm in an ascending order.  
The verbal script for the instruction was as follows: Different filaments will be 
applied to your foot. If you feel a sharp pain sensation, please indicate “NOW.” After a 
couple seconds, filaments will again be applied to your foot. At that time, if you first feel 
no pain, please indicate “NOW.” We are going to repeat this sensory test three times.  
 
 
 
Fig. 8. Thermode application 
 
 
 
The heat pain threshold was measured using a 9 cm2 Peltier thermode (ATS, 
Medoc Ltd., Israel, Fig. 8). Temperature was ramped at 1ºC/s (baseline temperature 32ºC) 
until participants indicated their first pain sensation or temperature reached to 52ºC. This 
method succeeded in detecting the threshold in all participants. The interval between the 
tests was 30s. The reported means of the heat pain threshold on the dorsum foot were 
43.8ºC (SD = 2.8) for young women and 45.1ºC (SD = 2.4) for young men (41). Another 
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study reports the median of the heat pain thresholds on the dorsum foot is 43.7 with the 
5th-95th percentiles of 38.3-47.6ºC (42).  
The verbal script for the instruction was as follows: You will feel a heat stimulus 
on your foot. The thermode will start at a low temperature and the temperature will slowly 
increase over time. Please respond by clicking the mouse as soon as the stimulus becomes 
painful. Remember, your first instinct may be to respond when the heat first turns on, but 
try to concentrate on clicking it only when you first feel pain. Remember to look at the 
black dot in front of you throughout the test. The test will only take a few minutes.  
The pressure pain threshold test was conducted using a handheld algometer 
(FPX 50 model, Wagner Instrument, CT, USA). An experimenter put a 1cm2 diameter 
rubber tip on a skin at a 90º angle (Fig. 9). Then, force was increased by 50kPa/s 
(~0.5kg/cm2s) until participants indicated that they first felt pain.  
 
 
 
Fig. 9. Algometer application 
 
 
 
The verbal script for the instruction was as follows: You will feel pressure on your 
foot. The pressure will slowly increase over time. Please say “STOP” as soon as the 
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stimulus becomes painful. Remember to look at the black dot in front of you throughout 
the test. The test will only take a few minutes. 
Enzyme-linked immunosorbent assay (ELISA) 
All samples were only thawed once before the analysis and duplicate samples were 
analyzed according to the manufactures’ manual. Abnova (Taipei, Taiwan, Cat. No 
KA1877) and IBL international (Hamburg, Germany, RE52061) kits were used for 
Epinephrine and Cortisol, respectively. Pre- and post- samples from the same subjects 
were all analyzed in the same plate. Although an attempt was made to reduce plate to plate 
variability by analyzing the same number of participants from each group in one plate, it 
was not entirely possible due to unequal n. Below, the ELISA procedures are briefly 
described. 
Before the Epinephrine ELISA procedures, sample preparation, extraction, and 
acylation were conducted at room temperature. Two 300μL aliquots of plasma were used 
for duplicate tests. Then, 250μL of distilled water, 50μL of assay buffer, and 50μL of 
extraction buffer were added into the respective wells of the extraction plate and the plate 
was incubated for 30 minutes on a shaker (VWR Model 3500). After the incubation, the 
plate was decanted and 1ml of wash buffer solution was added into each well. After this 
wash step was repeated one more time, 150μL of acylation buffer and 25μL of acylation 
reagent were added into each well and the plate was incubated for 15 minutes on a shaker. 
After emptying the plate, 1ml of wash buffer was added into all wells and the plate was 
incubated for 10 minutes on a shaker. After the incubation, the plate was decanted and 
was incubated again for 10 minutes with 150μL of hydrochloric acid.  
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The ELISA procedure was also performed at a room temperature. First, 25μL of 
the enzyme solution was added into all wells of the epinephrine microtiter plate. After 
adding 100μL of the extracted standards, controls, and samples into each well, the plate 
was incubated for 30 minutes on a shaker. The plate was incubated again for 2 hours with 
50μL of epinephrine antiserum, followed by three wash steps. Then, 100μL of the enzyme 
conjugate was added into all wells and the plate was incubated for 30 minutes on a shaker. 
After the incubation, the plate was washed three times and was incubated for 30 minutes 
with 100μL of the chromogenic substrate on a shaker. Then, 100μL of the stop solution 
was added and the optical density measures were read at 450nm on a Victor X3 Multilabel 
Plate Reader (PerkinElmer, Waltham, Massachusetts, USA). Finally, individual 
epinephrine levels were calculated by four-parameter logistic regression 
(www.myassay.com). The total assay time per plate from the sample preparation to ELISA 
was about 9 - 10 hours. According to the manual, the reference range of the plasma 
epinephrine is between 18 and 6,667 pg/mL. Intra- and inter-assay Coefficient of 
Variability (CV)s range from 11.0 to 24.7%. 
The cortisol ELISA was conducted using two 20μL aliquots of plasma. After 
putting 200μL of enzyme conjugate into each well, the plate was placed at room 
temperature for an hour incubation, followed by three wash steps. Then, 100μL of TMP 
substrate was added into each well and the plate was incubated for 15 minutes at room 
temperature. After adding 100μL of TMB stop solution into each well, the optical density 
measures were read at 450nm. Individual cortisol levels were calculated by a four-
parameter logistic regression (www.myassay.com). The total assay time per plate was 
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about 2.5 hours. The reference range of the plasma cortisol in the afternoon is 30-
160ng/mL (43). Intra- and inter-assay CVs range from 2.1 to 5.0%. 
Physiological Measures 
Continuous heart rate (HR), skin conductance level (SCL), and respiration rate 
(RR) were measured using a MP150, BIOPAC Systems, Inc. (Goleta, CA, USA), 
interfacing with AcqKnowledge software 4.2 for data acquisition. The sampling rate was 
1000Hz. LabVIEW 8.0 was also used to generate a digital signal from the National 
Instrument 6008USB device (Austin, TX USA) to STP100C, connecting to UIM100C 
(both BIOPAC Systems, Inc). Blood pressure was measured before and after the QST.  
A finite impulse response (FIR) band pass filter was used to remove the motion 
noise in HR (0.5 and 35Hz) (44) and RR (0.05 and 1.0 Hz) before calculating the rates. 
To remove artifact on SCL, 1 Hz FIR low pass filter was used. After filtering, all data 
were visually inspected. Filtering corrected most noise in RR and SCL. However, three 
subjects’ HR data during or after heat pain threshold testing were not analyzed for 
uncorrectable noises (e.g., extreme motion artifacts, detached sensors).  
3.2 Procedures 
Four female experimenters conducted this experiment. Two experimenters were 
involved in prescreening, scheduling, and providing preparation instruction. To increase 
the probability of recruiting individuals who consumed alcohol within 48 hours (i.e., the 
acute alcohol withdrawal phase), there was no preparation instruction about alcohol 
consumption, and the experiment was conducted from Thursday through Sunday. The 
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participants who consumed alcohol within 2 days were classified as acute alcohol drinking 
groups. Consequently, Experiment 1 included five naturally occurring groups: abstainers, 
moderate drinkers with and without acute alcohol drinking, and binge drinkers with and 
without acute alcohol drinking. Additionally, the experiment time was always from 12pm 
and 6pm to minimize the effect of diurnal variation on pain and stress hormones. Another 
experimenter obtained an informed consent, reviewed compliance of study preparation, 
checked vital signs before the first blood draw, and provided debriefing after pain testing. 
In cases of non-compliance with the study preparation, the experiment was rescheduled. 
The other experimenter who was blinded to participants’ drinking history drew blood and 
performed QST. After the QST, participants completed the questionnaires, which included 
first their guess about the study purpose, followed by alcohol related questionnaires (the 
AHS, ACQ, and recent drinking). None mentioned alcohol and all were blinded about the 
study hypothesis. 
Before and after the blood draw, BP, HR, and body temperature were measured to 
make sure the levels were within normal limits. Blood was drawn in a wet-lab space. A 
23g needle was used to draw 7ml of blood, which was collected in a chilled EDTA tube. 
Then, the blood samples were centrifuged for 15 minutes at 1000rcf in a cold room (4ºC), 
aliquoted into 0.5ml tubes, and stored in a -80⁰C freezer until being assayed. Most blood 
samples were drawn with one attempt; however, 4.5% of the samples were drawn with 
two attempts at pre- and post-QST each, and 0.6% and 2.3% of the samples were drawn 
with three attempts at pre- and post-QST, respectively. After the blood draw, participants 
walked to a sensory testing room located on the same floor as the wet lab and within a 1-
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minute walking distance. While moving from rooms, a water fountain, and a restroom 
were available. Participants were allowed to drink water and use the restroom as they 
desired.  
In the sensory testing room, sensors were applied before the survey, and the 
baseline physiological data were collected for 5 minutes after the survey. The interval 
between different QSTs was 5 minutes. No participants withdrew their consent during or 
after the laboratory testing. The timeline of the experiment is depicted in Fig. 10.  
 
 
1 2 3 4 5 6 7 
V/S 
BAC 
Blood 
draw 
Survey 
 QST  
Survey 
Blood 
draw 
V/S 
 MPT HPT PPT  
Physio Physio Physio 
Fig. 10. Experiment 1 timeline. [1 hour] V/S: Vital Sign (BP, HR, BT) MPT: Mechanical 
Pain Threshold, HPT: Heat Pain Threshold, PPT: Pressure Pain Threshold. 
 
 
 
3.3 Statistical Analysis 
The statistical assumptions were examined. Normality of each variable was 
evaluated with the Shapiro-Wilk’s test. If violated, variables were transformed, or 
appropriate nonparametric tests were used. Box plot and Mahalanobis Distance tests were 
conducted to screen for univariate and multivariate outliers, respectively. In case of 
extreme outliers (3+ SD or p < .001), nonparametric tests were used to reduce a Type I or 
II error (45). In cases of small number of outliers, parametric tests were conducted without 
the outliers. Box’s M test and Levene’s test were conducted to examine homogeneity of 
covariance matrices for MANOVA and homoscedasticity for ANOVA, respectively. A 
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liberal p value of .01 was used for the extremely sensitive Box’s M test (46). A correlation 
matrix was reviewed to evaluate multicollinearity issue (correlations > .90) for MANOVA 
(45).  
To examine the first hypothesis, a MANOVA with three pain thresholds was 
conducted, followed by least significant difference (LSD = t√
2𝑀𝑆𝑒𝑟𝑟𝑜𝑟
𝑛
 ). Although LSD 
dose not correct for familywise type I error, LSD was chosen because the sample size was 
calculated based on the large effect and the final sample did not have the sufficient number 
of participants in the group of interest (i.e., binge drinkers in the acute drinking phase). 
For the second hypothesis, an ANOVA was conducted to compare the group difference in 
stress hormones (i.e., epinephrine and cortisol) at baseline and their change scores (= the 
levels at post – baseline). If pain sensitivity would be different between the groups and the 
stress hormones showed parallel patterns, bias-corrected bootstrap mediational analysis 
would be conducted. Next, the relationship between negative affect and pain sensitivity 
was contrasted between the binge drinker groups and the other groups. Finally, an 
ANOVA was conducted to examine differences in alcohol craving between the groups. 
All statistical tests were two-tailed and p values less than .05 were considered significant, 
unless otherwise noted. SPSS 22 was used for all analyses except AMOS 18, which would 
be used for bias-corrected bootstrap analysis. 
Sample Size Calculation 
GPower 3.1 software was used to estimate the sample size. Large effects of alcohol 
withdrawal on pain threshold were reported in both animals and humans (Cohen’s d > 
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1.65). (6,7,17) Therefore, an f value of .4, a large effect size (Cohen, 1988), was used. 
This study was designed to recruit five naturally occurring groups: abstainers, moderate 
drinkers with and without drinking alcohol within 48 hours, and binge drinkers with and 
without drinking within 48 hours prior to the experiment. Throughout this paper, alcohol 
consumption within 48 hours is called “acute drinking.” The result of sample size 
calculation indicated that at least 16 participants would be needed in each group to achieve 
80% power and an α of .05 for a between-subjects design. To examine stress hormones as 
a mediator with bias-corrected bootstrap test, 34 binge drinkers would be needed for a 
large effect size with 80% power (46). The adequate sample size to detect the moderating 
role of negative affect was not pre-determined because this moderation effect was 
explorative in Experiment 1. To test the three hypotheses, the required sample size was 34 
participants per group. Despite efforts to meet this accrual target, recruitment of 34 
moderate and 34 binge drinkers in the acute drinking phase was not successful. 
Additionally, Experiment 1 was planned to recruit an equal number of men and women to 
control for the potential gender difference and the main interest was to evaluate the group 
differences by drinking patterns. Consequently, all the data were analyzed and presented 
by the group. However, gender by group interaction was examined and significant results 
would be noted if any. 
Missing Data 
There were few missing values (1.7%) and pairwise deletion was used. Details 
about the missing values are as follows. For pain data, three participants did not undergo 
heat pain threshold tests because of Medoc malfunctioning. Because these three 
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participants did not experience the heat pain threshold tests, their physiological and 
psychological state data during and after the heat pain test were not analyzed. 
Psychological trait variables had no missing values. To avoid missing by mistake, a popup 
window showed up on the screen prompting the participant to respond to unanswered 
items or to continue without answering. For psychological state variables, one abstainer 
and one moderate drinker did not complete the SAM-valence, arousal, and dominance 
throughout the experiment and one binge drinker did not complete the STAI at baseline.  
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4. RESULTS 
EXPERIMENT 1 
Of 179 consented participants, 177 participants completed this experiment. Two 
did not undergo the QST due to hypotension (systolic blood pressure was 80) at baseline 
and vasovagal syncope after the first blood draw. Demographics are shown in Table 1. 
There were no differences in gender, ethnicity, or cigarette use between the groups (ps > 
.097). The abstainer group was about one year younger than the other groups, but all were 
young adults. The typical number of drinks was on average 2-3 drinks for moderate 
drinkers and 4 (female)/6-8 (male) drinks for binge drinkers (Table 1).  
 
 
Table 1. Experiment 1 Demographics and drinking patterns 
 Abstainers Moderate drinkers Binge drinkers  
  No acute 
Drinking 
Acute 
drinking 
No acute 
Drinking 
Acute 
drinking  
 M(SD) M(SD) M(SD) M(SD) M(SD) F 
N 43 50 23 36 25  
(Male/Female) (20/23) (25/25) (17/6) (15/21) (14/11) 6.69 
% Caucasian 60.5 64.0 73.9 63.9 80.0 3.57 
% Cigarette use 2.3 6.0 13.0 13.9 8.0  
Age 18.7(1.2)a 20.1(2.5)b 20.3(2.0)b 19.8(1.8)b 19.6(2.3)ab 4.35* 
Typical drinks 
Men - 1.7(1.5) 3.3(2.3) 7.6(7.2) 5.5(2.9)  
Women - 2.3(1.1) 1.6(1.0) 4.2(2.3) 4.1(1.6)  
Ages at first 
drink  
- 18.0(1.9)a 16.8(1.9)b 17.1(1.3)b 16.5(1.0)b 4.87* 
Years of drink - 2.2(2.1) 2.8(1.9) 2.6(1.9) 3.0(2.3) 15.67 
Frequency - 2.0(1.4) 2.0(1.6) 2.6(1.5) 2.2(2.4) 0.82 
HSS - 3.0(2.8)a 4.0(3.0)a 5.1(3.0)b 6.6(2.9)c  
AHSχ - 5.6(3.7)a 5.6(3.0)a 6.3(4.0)a 10.2(9.3)b 4.94* 
Acute drinking: alcohol consumption within 48 hours before the experiment; * p < .005, 
χ2 statistics were used for gender and ethnicity; superscripts of a and b indicate significant 
difference in post hoc analysis; AHS: Acute Hangover Scale. 
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The age of the first alcohol use was somewhat later in moderate drinkers than the 
others, but no significant difference was found in years of regular alcohol use (p = .448). 
On the DDQ prescreening questionnaire, frequency of drinking for the past month was 
evaluated. The survey has a nominal scale, ranging from 0: not drink at all to 7: once a 
day or more. The results of an ANOVA indicated no significant difference in the 
frequency. All types of drinkers endorsed drinking alcohol on average about twice a 
month. However, binge drinkers reported more experiences of hangover symptoms for the 
past 12 month on the HSS in their prescreening survey. Notably, the HSS scores were 
even higher in the binge drinkers with acute drinking than those without. As expected, 
more acute hangover symptoms were reported by binge drinkers with acute drinking, 
validating the self-reported recent drinking episode.  
4.1 Psychological Traits 
Psychological traits were only significantly different between the groups for 
depressive symptoms. The results of the Kruskal-Wallis test indicated a significant 
difference in depressive symptoms (p = .022), but not in anxiety symptoms (p =.166) or 
stress levels (p = .671). Post-hoc pairwise comparison with the Mann-Whitney test showed 
that moderate drinker and binge drinker groups reported higher levels of depression than 
the abstainer group (Table 2). Depressive symptoms were not different between the 
abstainer and moderate drinker group with acute drinking (p = .075). 
The result of an ANOVA indicated the total PSS scores also did not differ between 
the groups (p = .329), suggesting perceived levels of stress were similar between the 
groups with different drinking patterns. In the 2 (gender) by 5 (group) ANOVA, there was 
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a significant gender difference, F (1, 167) = 4.58, p = .034, η2 = .027 with women (M = 
17.8, SD = 6.0) reporting higher levels of stress than men (M = 15.5, SD = 5.7). No gender 
by group interaction was observed (p = .401). 
 
 
Table 2. Experiment 1 Psychological traits 
 Abstainers Moderate drinkers Binge drinkers 
  No Acute 
Drinking 
Acute 
drinking 
No Acute 
Drinking 
Acute 
drinking 
 M SD M SD M SD M SD M SD 
DASS-DEP 3.8a 5.2 6.2b 7.2 5.9ab 6.5 5.3b 5.1 7.9b 7.3 
DASS-ANX 4.1 4.5 4.8 5.0 3.7 3.7 4.6 5.1 6.3 4.5 
DASS-STR 8.9 6.0 8.9 6.3 8.6 6.6 9.3 6.6 11.0 6.7 
PSS 15.5 5.7 16.3 6.1 16.1 5.9 17.9 5.5 17.9 6.8 
BIS-Total* 4.1 0.2 4.1 0.2 4.1 0.1 4.1 0.2 4.2 0.2 
BIS-
ATTEN* 
2.8 0.2 2.8 0.2 2.9 0.2 2.8 0.2 2.8 0.3 
BIS-
MOTOR* 
3.0 0.2 3.0 0.2 3.1 0.2 3.1 0.2 3.1 0.2 
BIS-PLAN* 3.1 0.2 3.2 0.2 3.1 0.2 3.2 0.2 3.2 0.2 
ACQ-Total* 3.0a 0.3 3.2b 0.3 3.3b,c 0.3 3.3b,c 0.4 3.6c 0.3 
ACQ-COMP 3.5 1.6 3.7 1.6 4.6 2.8 4.0 2.0 4.5 2.3 
ACQ-XPCT 4.5a 2.0 6.9b 3.5 6.8b 3.3 7.6b 3.8 8.0b 3.3 
ACQ-PURP 6.9a 3.8 9.0b 3.9 10.4b 4.0 10.4b 4.6 10.0b 3.4 
ACQ-EMOT 5.5 3.2 5.6 3.6 5.8 3.4 6.3 3.8 7.5 4.5 
DASS (Depression Anxiety Stress Scales)-DEP: Depression, ANX: Anxiety, STR: Stress; 
PSS: Perceived Stress Scale; BIS (Barratt Impulsiveness Scale)-ATTEN: Inattention, 
MOTOR: Motor Restlessness, PLAN: Non-Planning; ACQ (Acute Craving 
Questionnaire-NOW)-COMP: Compulsivity; XPCT: Expectancy; PURP: Purposefulness; 
EMOT: Emotionality; superscripts of a, b and c indicate significant difference in post hoc 
analysis. * log transformed. 
 
 
 
The result of an ANOVA indicated that BIS scores were not significantly different 
between the groups (p = .315, Table 2). Therefore, the levels of impulsivity were similar 
between the groups with different drinking patterns. When analyzing the three subscale 
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scores with a MANOVA, the levels of inattention, motor restlessness and non-planning 
were similar between the groups (p = .556). 
Finally, the result of an ANOVA with LnACQ total scores showed a group 
difference in alcohol craving after the pain testing, F (4, 169) = 7.19, p < .001, Table 2. 
The results of post hoc analysis with LSD showed that alcohol craving was greater in 
moderate and binge drinker groups than the abstainer group. Furthermore, the binge 
drinker group with an acute drinking episode showed greater craving than the moderate 
drinker group without acute alcohol drinking. Consequently, acute alcohol withdrawal 
might further enhance craving for alcohol. 
Additional analysis with the four ACQ subscale scores (compulsivity, expectancy, 
purposefulness, and emotionality) were conducted to further examine whether the group 
difference in overall craving was related to specific aspects of craving. After removing the 
three multivariate outliers (1 abstainer, 2 binge drinkers), a MANOVA was conducted. 
The results indicated a main effect of group, Wilk’s Λ = .78, p < .001. The follow-up 
univariate analysis showed that only expectancy, F (4, 169) = 6.95, p < .001, partial η2 = 
.14, and purposefulness, F (4, 169) = 4.82, p = .001, partial η2 = .10, were different 
between the groups. LSD post-hoc analysis indicated that expectancy and purposefulness 
scores were higher in the moderate- and binge-drinker groups than the abstainer group. 
Acute drinking episode did not further enhance craving for both the moderate and binge 
drinker groups evidenced by no significant differences between the drinking groups with 
and without acute drinking, ps > .627. Taken together, the data showed differences 
between abstainers and drinkers in urges and desires to drink alcohol in expecting the 
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positive aspects of drinking and with intentions or plans to drink, but there was no 
difference between moderate and binge drinkers.  
 
 
Table 3. Experiment 1 Baseline psychological and physiological states 
 Abstainers Moderate drinkers Binge drinkers 
  
No Acute 
Drinking 
Acute 
Drinking 
No Acute 
Drinking 
Acute 
Drinking 
 M SD M SD M SD M SD M SD 
Psychological State 
STAI 9.2 2.3 9.2 2.3 9.4 2.5 9.4 3.1 9.4 2.6 
PANAS-PA 31.7 6.7 30.9 6.5 31.9 8.9 29.2 7.7 30.0 6.9 
PANAS-NA 12.8 3.2 12.9 3.1 12.4 1.8 12.4 2.5 14.0 4.2 
SAM-V 6.6 1.6 6.4 1.3 6.0 1.8 6.6 1.5 5.9 1.2 
SAM-A 3.3 1.9 3.1 1.8 3.3 2.1 3.4 2.1 3.7 1.4 
SAM-D 5.4 1.9 4.8 1.6 5.5 2.0 5.4 1.9 5.3 1.6 
Physiological State 
HR(beat/min) 72.7 8.9 75.6 10.7 72.0 9.5 74.3 10.1 72.8 9.5 
sqrtSCL(μS) 2.0a 0.7 2.5b 0.8 2.5b 0.6 2.1ab 0.6 2.4b 0.8 
RR(breath/min) 13.6 3.9 14.2 2.8 14.1 3.3 13.2 3.2 13.9 3.0 
SBP(mmHg)* 112.0 10.0 114.5 13.1 119.4 13.7 113.9 12.7 116.8 12.9 
DBP(mmHg)* 70.6 5.7 71.8 7.4 72.7 10.2 72.1 9.0 71.0 6.5 
STAI: State-Trait Anxiety Inventory-6, PANAS (Positive and Negative Affect Schedule)-
PA: Positive affect, NA- Negative affect, SAM (Self-Assessment Manikin)-V: Valence, 
A-Arousal, D: Dominance; HR: Heart Rate, SCL: Skin Conductance Level, RR: 
Respiration; SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure;*: Kruskal-
Wallis followed by Mann-Whitney U. 
 
 
 
4.2 Baseline Psychological and Physiological States 
All baseline psychological states were similar across groups as indicated by non-
significant results of Kruskal-Wallis tests (ps > .136). For the baseline physiological states, 
a one-way ANOVA indicated difference in sqrtSCLs, F(4, 283) = 3.12, p = .017, partial 
η2 = .07. LSD post-hoc analysis indicated that higher SCLs were observed in the two 
moderate drinker groups and the binge drinker group with acute drinking, ps < .05 (Table 
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3). No significant group difference was found in HR, F (4, 172) = 0.86, p = .488, and RR, 
F (4, 172) = 0.56, p = .692. The Kruskal-Wallis tests were conducted to compare blood 
pressures (systolic and diastolic). Systolic (SBP) and diagnostic blood pressure (DBP) 
were not different between the groups (ps > .310).  
In controlling for ethnicity (White = 1 vs other ethnicity = 0), group difference in 
SCLs remained significant (p = .018). However, LSD post hoc analyses showed that 
higher levels of SCL were observed only in the two moderate drinker groups, not in the 
binge drinker group with acute alcohol use. 
4.3 Pain Sensitivity 
To examine the group difference in mechanical, heat, and pressure pain thresholds, 
a MANOVA was conducted. The result indicated a main effect of group, Wilk’s Λ = .80, 
p < .001. The result of the follow-up univariate analysis indicated that only pressure pain 
threshold (log transformed) was different between the groups, F(4, 165) = 7.10, p < .001, 
and this was a large effect (partial η2 = .14). No significant group difference was observed 
in mechanical pain threshold (log transformed, p = .148) or heat pain threshold (p = .393). 
LSD post-hoc analysis indicated that the binge drinker group without acute drinking, M = 
1.02, SD = 0.50, showed reduced pressure pain thresholds when compared to the moderate 
drinking group without acute drinking, M = 1.27, SD = 0.47, p = .013, Fig. 11. These 
results indicate the divergent effects of alcohol consumption on pressure pain threshold. 
Specifically, moderate drinking was associated with a slight increase in pressure pain 
threshold whereas binge drinking was associated with a slight decrease in pressure pain 
threshold. Additionally, the binge drinker group with acute drinking, M = 0.67, SD = 0.51, 
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showed reduced pressure pain threshold compared to all the other groups, ps < .005. The 
difference between the binge drinker groups with and without acute drinking indicated 
that acute alcohol withdrawal was associated with further reduction in pressure pain 
thresholds. Lastly, the result indicated that binge drinking and acute alcohol withdrawal 
might not influence cutaneous mechanical and heat pain threshold in young adult binge 
drinkers.  
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Fig. 11. Comparison of mechanical, heat, and pressure pain thresholds between the groups 
with different drinking patterns. Error bars = SEM. 
 
 
 
4.4 The Role of Stress Hormones in Pain Sensitivity 
First, the group differences in the baseline epinephrine levels were examined (Fig. 
12, left). Because of gender difference in epinephrine levels, a 2 (gender) by 5 (group) 
ANOVA was conducted. The result indicated a significant main effect of group, F(4, 167) 
= 2.50 p = .044, partial η2 = .06, and gender, F(4, 167) = 7.89, p = .006, partial η2 = .05, 
but no significant interaction (p = .938). For a significant main effect of gender, the basal 
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epinephrine levels were higher in the men (M = 247.4, SD = 202.5) than the women (M = 
164.5, SD = 151.0).  
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Fig. 12. Comparison of baseline epinephrine levels and their responses to pain between 
the groups with different drinking patterns. Error bars = SEM. 
 
 
 
LSD post-hoc analysis showed that regardless of acute drinking, the two binge 
drinker groups showed elevated epinephrine at baseline compared to the abstainer group. 
Additionally, the binge drinker group without acute alcohol drinking showed elevated 
epinephrine levels compared to the moderate drinker group without acute alcohol 
drinking. Different from expectation, no significant difference was found between the 
binge drinkers with and without acute drinking. These results suggested that binge 
drinking was associated with increases in basal epinephrine levels, but acute alcohol 
withdrawal was not associated with further increase in epinephrine levels. This 
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epinephrine pattern did not completely corresponding to the pattern of pressure pain 
thresholds. In particular, the binge drinker group with acute alcohol drinking did not show 
the highest elevation and only differed from the abstainer group. Therefore, a bias-
corrected bootstrap test was not performed. However, binge drinkers showed higher 
epinephrine levels than the moderate drinkers when they had not drunk alcohol within 48 
hours. Another similarity was that the binge drinker group with acute drinking showed 
higher levels of epinephrine than the abstainer group. This suggests that basal epinephrine 
levels may contribute to binge drinking-induced hypersensitivity to pressure pain. 
Subsequently, an ANCOVA with basal epinephrine levels as a covariate was conducted. 
In controlling for basal epinephrine levels, the group difference in pressure pain threshold 
remained significant, F (4, 171) = 6.21, p < .001, but the effect size was reduced by 7%, 
partial η2 = .13. This suggests that epinephrine did not fully account for the group 
difference in pressure pain thresholds, but it explained a small portion of the variance 
(7%).  
The Kruskal-Wallis test was conducted to examine whether epinephrine responses 
to laboratory pain testing were significantly different between the groups (Fig. 12, right). 
This analysis used the change score (= the levels at post-pain testing– the baseline). The 
result indicated no significant group difference (ps = .727). Overall, epinephrine levels 
were elevated after the QSTs (M = 0.6, SD = 3.8).  
Next, the group difference in the baseline cortisol levels was examined (Fig. 13, 
left). Because of gender difference in cortisol levels, a 2 (gender) by 5 (group) ANOVA 
was conducted. The result indicated a significant main effect of gender, F (1, 167) = 4.19, 
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p = .040, η2 = .02, but no significant main effect of group (p = .215) or group by gender 
interaction (p = .402). Similarly to the epinephrine pattern, the cortisol levels were higher 
in the men (M = 123.2, SD = 45.1) than the women (M = 105.8, SD = 38.2). The lack of a 
group difference in cortisol suggests that basal cortisol did not contribute to the group 
difference in pressure pain threshold.  
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Fig. 13. Comparison of baseline cortisol levels and their responses to pain between the 
groups with different drinking patterns. Error bars = SEM. 
 
 
 
The Kruskal-Wallis test was conducted to examine whether cortisol responses to 
laboratory pain testing were significantly different between the groups (Fig. 13, right). 
The result indicated no significant group difference (p = .435). On average, cortisol levels 
were decreased after the QSTs (M = -26.8, SD = 30.5). This cortisol response to pain 
testing is different from epinephrine response; the former showed reduction and the latter 
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showed elevation at post-pain testing. The baseline levels of epinephrine and cortisol were 
unrelated (Pearson r = -.06, p = .446). 
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threshold) were compared across the groups with different drinking patterns.  
 
 
 
4.5 The Role of Negative Affect in Pain Sensitivity 
The Pearson correlation coefficients between state anxiety and pain sensitivity 
were compared between the binge drinker and the abstainer groups (Fig. 14). A significant 
relationship was found only in the abstainer group, with higher levels of anxiety at baseline 
as being associated with lower pressure pain thresholds (r = -.54, p < .001). The same 
pattern was observed with other measures of pain sensitivity, with the abstainer group 
reporting greater anxiety at baseline associated with lower mechanical (r = -.37, p = .013) 
and heat pain thresholds (r = -.34, p = .027). Different from our expectation, this result 
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showed binge drinking and acute withdrawal eliminated the relationship between baseline 
negative affect and pain sensitivity. To note, changes in anxiety levels by the three QSTs 
was minimal (M = 0.07, SD = 2.42) and the Kruskal-Wallis test indicated no group 
difference (p = .732). Psychological traits (depression, anxiety, and stress levels) and their 
interactions with the group did not predict mechanical, heat, and pressure pain thresholds 
(ps > .101). 
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Fig 15. Changes in the SAM-valence, arousal, and dominance in response to pain tests 
 
 
 
4.6 Psychological Responses to Pain Testing 
First, changes in SAM-valence scores were compared between the groups, Fig. 15, 
the top. The result of a 4 (time) by 5 (group) repeated measures ANOVA showed a 
significant change over time, F (3, 438) = 21.89, p < .001, Greenhouse-Geisser ε = .86 
without significant interaction (p = .311). A linear function best fit the data, suggesting 
that unpleasant emotion decreased over time, F (1, 170) = 38.25, p < .001. 
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With the SAM-arousal scores, a 4 (time) by 5 (group) repeated measures ANOVA 
was conducted. The result showed a significant change over time, F (2, 415) = 17.07, p < 
.001, Greenhouse-Geisser ε = .81 without significant interaction (p = .135). A quadratic 
function best fist the data, F (1, 170) = 28.40, p < .001. LSD post-hoc analysis showed 
that the levels of perceived arousal increased up to the second pain testing, but decreased 
upon completion of the last pain testing. 
Lastly, the result of a 2 (time) by 5 (group) repeated measures ANOVA showed 
no significant change in the SAM-dominance scores, F (2, 423) = 1.30, p = .274, 
Greenhouse-Geisser ε = .83, and no significant interaction (p = .787).  
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Fig. 16. Changes in HR, SCL, and RR before, during, and after pain testing 
 
 
 
4.7 Physiological Responses to Pain Testing 
Changes in HR were compared between the groups, Fig. 16, top. A 3 (time: 
baseline, pain testing, final) by 5 (group) repeated measures ANOVA was conducted. 
Because HR pattern was unchanged across different pain tests, the average HR for the 
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entire duration of pain tests were used. The result indicated a significant main effect of 
time, F (4, 742) = 5.48, p < .001, Greenhouse-Geisser ε = .74, but no interaction (p = .425). 
LSD post hoc analysis showed that HR was slightly elevated during pain testing (M = 
74.7, SD = 9.5) and remained elevated for the 5 minutes after the pain testing (M = 74.5, 
SD = 9.7) compared to the baseline (M = 73.6, SD = 9.8).  
Changes in SCL were compared between the groups, Fig. 16, middle. A 3 (time: 
baseline, pain testing, final) by 5 (group) repeated measures ANOVA was conducted. 
Again, the SCL pattern was unchanged across different pain tests. Therefore, the average 
SCL for the entire duration of pain tests were used. The result indicated a main effect of 
time, F (1, 214) = 212.6, p < .001, Greenhouse-Geisser ε = .63 and significant interaction, 
F (5, 214) = 3.17, p = .009. LSD post hoc analysis showed that SCL was elevated during 
pain testing (M = 2.8, SD = 0.6) compared to the baseline (M = 2.3, SD = 0.7), but it was 
slightly recovered after the pain testing (M = 2.7, SD = 0.6) as indicated that the level at 
the final was different from the levels at baseline (p < .001) and during pain testing (p < 
.001). Another post-hoc test for the interaction was conducted. The results indicated that 
initially different SCLs were no longer different during, F (4, 170) = 1.05, p = .382, and 
after pain testing, F (4, 170) = 0.99, p = .414. SCR to mechanical, heat, and pressure pain 
thresholds were also compared between the groups. The results of ANOVA showed no 
significant group difference (ps > .231).  
Changes in RR were compared between the groups, Fig. 16 bottom. A 3 (time: 
baseline, pain testing, final) by 5 (group) repeated measures ANOVA was conducted. 
Because the RR pattern was unchanged across different pain tests, the average RR for the 
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entire duration of pain tests was used. The result indicated a main effect of time, F (2, 309) 
= 22.70, p < .001, Greenhouse-Geisser ε = .91, but no interaction (p = .472). LSD post hoc 
analysis showed that similar to SCL, RR was elevated during pain testing (M = 14.9, SD 
= 2.3) compared to the baseline (M = 13.8, SD = 3.3). Additionally, RR was slightly 
recovered after the pain testing (M = 14.6, SD = 2.8) as indicated that the rate at the final 
was different from the levels at baseline (p < .001) and during pain testing (p < .001). 
To compare SBP changes between the groups, a 4 (time: baseline, post-mechanical 
pain thresholds, post-heat pain threshold test, final) by 5 (group) repeated measures 
ANOVA was conducted. The results showed a main effect of time, F (3, 504) = 5.28, p = 
.001, but no interaction (p = .572). LSD post hoc analysis showed SBP reduced after heat 
(M = 113.0, SD = 12.2, p = .005) and pressure pain threshold tests (M = 112.4, SD = 11.9, 
p = .001) compared to the baseline (M = 115.0, SD = 11.7).  
Changes in DBP were also compared between the groups. The result of a 4 (time: 
baseline, post-mechanical pain threshold, post-heat pain threshold, final) by 5 (group) 
repeated measures ANOVA showed no main effect of time (p = .090). A main effect of 
group was found, F (3, 504) = 5.28, p = .001, but the results of LSD post hoc analysis 
were not significant (ps > .688). Throughout the experiment, DBP levels remained 
unchanged.  
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5. EXPERIMENT 2 
Experiment 2 was a within-subject design to examine alcohol-withdrawal induced 
hyperalgesia in young adult binge drinkers with laboratory alcohol administration. 
Experiment 2 included mechanical, heat, and pressure pain thresholds to test replicability 
of Experiment 1 findings and added capsaicin-induced pain responses such as spontaneous 
burning pain on the site of application, primary and secondary hyperalgesia, and flare. To 
administer alcohol in the laboratory, Experiment 2 raised the minimum age to 21 years 
old. Additionally, Experiment 2 recruited students (undergraduates and graduates) and 
employees using university-listserv emailing method only. All the other eligibility criteria 
were the same. To avoid redundancy, only measures and procedures that are different from 
Experiment 1 are described below.  
The four specific objectives for Experiment 2 were as follows. The first objective 
was to examine whether alcohol withdrawal would enhance spontaneous pain, primary 
and secondary hyperalgesia, and capsaicin-induced flare. The second objective was to 
examine whether stress hormones (i.e., epinephrine and cortisol) would be correlated with 
alcohol withdrawal-induced hyperalgesia and flare. Third, this study examined whether 
negative affect (i.e., depression and anxiety) would enhance alcohol withdrawal-induced 
hyperalgesia. The last objective was to examine whether pain and alcohol-withdrawal 
would enhance alcohol craving.  
It was hypothesized that binge drinkers would show enhanced capsaicin-induced 
pain and this pain hypersensitivity would be further enhanced during acute alcohol 
withdrawal. Additionally, stress hormones were expected to be increased in binge drinkers 
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at baseline and be further enhanced during acute alcohol withdrawal. Next, more negative 
affect during alcohol withdrawal would enhance withdrawal-induced hyperalgesia. Lastly, 
alcohol withdrawal and pain would increase alcohol craving.  
A certificate of confidentiality was obtained from the NIAAA to protect the 
privacy of participants. Texas A&M University Institutional Review Board approved the 
study procedures and informed consent was obtained from all participants. 
Participants were recruited from June of 2015 to April of 2016. Of the total 657 
women and 565 men who completed the online prescreening survey (Mage = 23.1, SDage = 
2.3, 21-30 years), 5 people did not provide a response for their current drinking pattern. 
Of the total 1,217 responders, 6% endorsed being former drinkers and 79% endorsed being 
current drinkers. This differs from Experiment 1, where abstinence was the most common 
(57%), heavy drinking (34%) was the most common in Experiment 2, followed by 
moderate (24%) and binge drinking (21%), Fig. 17. About a fourth of individuals who 
completed the prescreening were not invited due to ineligibility criteria. 
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Fig. 17. Experiment 1 prevalence of different drinking patterns in young adults 
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Of the total 946 eligible participants who were invited via email, 54 people were 
consented and 41 participants completed the study. Of those who completed the study, 
five people were excluded because the exit interview with the SCID-I revealed that they 
underreported their current drinking on the prescreening survey. These five people were 
replaced and recruitment was continued until the study had 12 each of abstainers, moderate 
drinkers, and binge drinkers. Although the study intended to recruit equal number of men 
and women for all drinking pattern, abstainers consisted of five females and seven males 
because miscoded gender on the recruitment tracker was found after recruitment was 
completed. Of the 13 participants who were consented, two did not undergo QST because 
their ineligibility condition was found after consenting. One had skin condition on the pain 
testing sites and the other reported pain from sprained toes. Three participants were 
removed by the experimenter after the QST was completed on the first visit because of the 
following reasons. One participant experienced vasovagal syncope at the blood draw after 
the QST. Another participant endorsed drinking within two days after the QST. Lastly, 
one participant who expressed extreme worry over blood tests was removed from the 
study. The rest (n = 9) completed their first study visit, but withdrew their consent or did 
not show up for the subsequent visits. Most people who drank juice or alcohol on the 
second visit showed up for their last study visit except two female binge drinkers who 
consumed alcohol on the second visit, but did not show up on the next day.  
When using the DSM-IV diagnostic criteria, 33.3% of binge drinkers met the 
current diagnostic criteria for alcohol abuse and 25.0% met the diagnostic criteria for 
alcohol dependence. Some moderate drinkers also met the current (16.7%) and lifetime 
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(8.3%) diagnostic criteria for alcohol abuse. Two moderate drinkers did not have a current 
problem, but met lifetime diagnostic criteria for alcohol dependence. In using the DSM-5 
diagnostic criteria, 75% (58.3% mild, 8.3% moderate, and 8.3% severe) of binge drinkers 
met the diagnostic for alcohol use disorder. Additionally, 23.1% of moderate drinkers met 
the diagnostic criteria for mild alcohol use disorder. Using the AUDIT (the total score 8+), 
3 moderate drinkers (25%) and 5 binge drinkers (42%) were identified as having 
problematic drinking behaviors. 
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6. METHODS 
EXPERIMENT 2 
6.1 Measures 
In addition to the measures used in Experiment 1, the following psychological trait 
measures were added in Experiment 2. 
Self-report 
The UPPS Impulsive Behavior Scale (UPPS) is a 45-item self-report 
questionnaire to assess four dimensions of impulsivity such as lack of premeditation, 
urgency, sensation seeking, and lack of perseverance. The scale ranges from 1: agree 
strongly to 4: disagree strongly and higher total summed scores indicates more impulsive 
behavior (Cronbach’s αs =.83 - .89) (47).  
The Zuckerman-Kuhlman Personality Questionnaire–Impulsive Sensation 
Seeking subscale (ZKPQ-ImpSS) is a true/false questionnaire to assess impulsivity with 
19 items (Cronbach’s αs =.64 - .80) (48,49). This subscale measure assesses a lack of 
planning and a tendency to act impulsively and to seek excitement and novel experiences. 
Higher scores indicate higher levels of impulsivity and sensation seeking tendency.  
The Biphasic Alcohol Effects Scale (BAES) is a self-report to measure of the 
subjective acute stimulant (7 items, Cronbach’s α = .94) and sedative effects (7 items, 
Cronbach’s α = .85) of alcohol (50). The scale ranges from 0: not at all to 10: extremely. 
The possible total summed scores range from 0 to 70 for each effect. The BAES was 
administered on the last study to assess the effect of consumed alcohol in the laboratory 
on the previous night. 
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The Alcohol Use Disorders Identification Test (AUDIT) is a measure widely 
used measure to detect individuals with problematic drinking (Cronbach’s α = .81) (51). 
This 10-item measure has acceptable sensitivity (.81), specificity (.95), and diagnostic 
accuracy (AUC = .97) (51).A cutoff score of 8 has been suggested to maximize sensitivity 
to the mid .09s (52). This measure also has acceptable sensitivity (.84) and specificity (.71) 
for college students (53). This measure was administered on the last study visit. 
The Structural Clinical Interview for DSM-IV Axis I Disorder (SCID-I)-
Alcohol Abuse and Dependence module is a semi-structured interview for the diagnosis 
of alcohol abuse and dependence for the lifetime alcohol use problems. The new DSM-5 
diagnostic criteria exclude a prior legal problem item and include a new item assessing 
focused attention on alcohol use (10). The DSM-5 does not use the term alcohol abuse and 
dependence, but instead uses a new term, alcohol use disorder with different severity 
(mild, moderate, and severe).  
Quantitative Sensory Testing (QST) 
Pain testing was conducted on the dorsum of the feet. To measure changes in 
mechanical pain sensitivity before and after topical capsaicin on the application site and 
the non-application site, a grid was drawn on both feet before the QSTs (Fig. 18, left). The 
middle of the foot was marked with a 1.6cm diameter circle for the capsaicin application 
site and eight spokes of a 5cm length line were drawn at 45º angle. On each spoke, 10 dots 
spaced 0.5cm apart were marked with a washable marker for evaluating pain intensity 
with a 26gF von Fey filament. To draw the grid on the anatomically same location on the 
dominant foot, the second toe was used as an index for the central line. The von Frey was 
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applied first to the non-dominant foot, starting from the furthest point and moving towards 
the capsaicin application site. The first test always started from the second toe, then moved 
to the opposite spoke to avoid local influence, and moved to the outer side (toward the 5th 
phalange, Fig. 18, left).  
 
 
 
Fig. 18. The grids on the pain testing sites (left) and electronic von Frey application 
(right) 
 
 
 
Participants marked the pain intensity after each von Frey application on paper 
using a VAS. For the mechanical pain thresholds, an electronic von Frey anesthesiometer 
with semi-flexible tip (Almemo 2450, IITC Inc, Life Science, Wooland Hill, CA) was 
applied to the capsaicin application site (non-dominant foot) and the counterpart 
(dominant foot), Fig. 18, right. Participants were instructed to say “NOW” when they first 
felt a sharp pain sensation. Three mechanical pain threshold tests were conducted at 10s 
intervals. The average of the three was used for the analysis. The protocols for assessing 
1st 
2nd 
3rd 
4th 
5th 
6th 
7th 
8th 
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heat and pressure pain thresholds were the same as Experiment 1 and tested on the non-
dominant foot.  
Capsaicin Application First, 0.3ml of 6% capsaicin solution dissolved in a 50% 
ethanol (Cat No. 360376-1G, Sigma Aldrich Inc,) was placed on a 1.5cm diameter filter 
paper. Then, the capsaicin-containing filter paper was applied for 30 minutes to the center 
of the non-dominant foot and the site was covered with 6cm × 7cm Tegaderm (3M, St. 
Paul Minnesota, USA, Fig. 19). The vehicle, 0.3ml of 50% ethanol solution applied to the 
same size filter paper, was applied to the dominant foot. About 16ml of 6% capsaicin 
solution was premade every 6 month and stored at a 4ºC in a refrigerator. The solution 
was kept on a room temperature for about 30 minutes before use.  
 
 
Fig. 19. Capsaicin application on a filter paper 
 
 
 
Visual Analogue Scale (VAS) A paper version of the visual analogue scale (VAS) 
was used to evaluate sensory and affective pain intensity. The VAS is a 10cm horizontal 
line, anchored by words and numbers at each end: 0: not at all painful and 10: the most 
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intense pain imaginable for sensory pain intensity and 0: not at all unpleasant and 10: the 
most unpleasantness imaginable for affective pain intensity (54). Distance from the zero 
measured in cm to one decimal point was used for intensity.  
Primary Allodynia Mechanical pain thresholds were measured three times on the 
capsaicin and vehicle solution application site before and after the solution application. 
Primary hyperalgesia was measured by calculating the difference score before and after 
the capsaicin application. Changes in pain threshold would reflect sensitization or 
desensitization.  
Secondary Allodynia Area of secondary allodynia was determined with two 
methods. The first method was to calculate the size of the area where a persistent increase 
in pain intensity occurred compared to the furthest point on each spoke. This method 
assumes pain sensitivity on the entire dorsal surface of the foot is the same. The total 
possible values range from 1.8 (the size of the application) to 93.8cm2. The second method 
was to calculate the size of the area where pain intensity increased compared to the 
baseline. This method assumes that pain sensitivity on the surface is not the same so that 
direct point-by-point comparisons should be made before and after the capsaicin 
application. The possible total values range from 1.8 to 111.5cm2. These two methods 
were also used to calculate areas of hyperalgesia on the vehicle foot to evaluate central 
sensitization. 
Laser Doppler Imaging A laser Doppler imager (MoorLDI2-IR model, Moore 
Instruments Ltd., London, UK) was used to assess capsaicin-induced neurogenic flare 
reaction. This LDI scan (256×256 pixels; spatial resolution of 4ms/pixel) was placed at a 
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distance of 50cm from the skin. The scan was performed immediately after the 30 minutes 
of capsaicin application and took about 5 minutes per image. The scanned image was 
analyzed offline using the Moore LDI image review 5.3 software to calculate size (cm2) 
and intensity (arbitrary perfusion units: PU) of the erythematous flare reactions. The size 
of flare was calculated for the zones of hyperemic responses (> 300 PU) (55,56). The 
participants were asked to lay on a table in a supine position, to keep their foot flat, and to 
stay still for 5 minutes. For those who were unable to stay still, the experimenter held their 
knee with permission (Fig. 20). 
 
 
 
Fig. 20. Laser Doppler imaging to measure flare in a supine position 
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Physiological Measures Collection, cleaning, and analysis method for 
physiological data were the same as Experiment 1. After filtering, two subjects’ HR data 
during the last von Frey pain tests were not analyzed due to uncorrectable noise.  
Epinephrine and Cortisol ELISA The procedure for the blood draw and ELISA 
were the same as in Experiment 1.  
Breathalyzer A breathalyzer test was performed to estimate BACs with BACtrack 
S75 Pro breathalyzer. This breathalyzer measures BAC from 0.000 to 0.400% with ± 
0.005 error at 0.100% BAC (manufacture’s manual). On the second study visit for alcohol 
administration, participants were instructed to rinse their mouth thoroughly with tap water 
at least twice before each breathalyzer test. 
6.2 Procedures 
This study consisted of three study visits and the experiment timeline for each 
study was depicted in Fig. 21. The interval between different QSTs was always 3 minutes. 
The LDI scanner was located outside the pain testing room. Therefore, participants walked 
a few steps after the sensors were detached. The experiment on Visit 1 and 3 took about 
2.5 hours. The interval between the first and third visit was 7 ± 2 days and the second visit 
was one day before the third visit. The start time was 9am ± 30 min on Visit 1 and 3, and 
8:30pm ± 30 min on Visit 2. This means that QST on Visit 3 occurred 12 to 12.5 hours 
after the last drink. Before Visits 1 and 2, participants were instructed not to drink alcohol 
for three days, in order to assess their baseline pain sensitivity while not under the 
influence of the acute alcohol and to evaluate the effect of alcohol only consumed at the 
laboratory, respectively. After Visit 2, the participants were again instructed not to drink 
 58 
additional alcohol. Before alcohol administration, a breathalyzer test and a urine 
pregnancy test (female only) were conducted to ensure zero BAC and no alcohol 
administration to a pregnant woman, respectively.  
 
 
Visit 1 (Baseline) & Visit 3 (5±2 days after Visit 1): 9am-11:30am 
1 2 3 4 5 6 7 
V/S 
BAC 
Blood 
draw 
Survey 
 QST  
Survey 
Blood 
draw 
V/S 
 VF 
MPT 
HPT 
PPT 
Capsaicin 
Spontaneous 
pain 
Scan 
Flare 
VF 
MPT 
 
Physio Physio  Physio Physio 
Visit 2 (Alcohol/Juice Administration):8:30pm ~ midnight, one day before Visit 3 
1 2 3 4 
V/S 
BAC 
Pregnancy test 
(female only) 
Alcohol/Juice 
(30 min) 
BAC 
Fig. 21. Experiment 2 timeline. V/S: Vital Sign (BP, HR, BT), VF: Von Frey on the grid, 
MPT: Mechanical Pain Threshold, HPT: Heat Pain Threshold, PPT: Pressure Pain 
Threshold 
 
 
 
A standardized alcohol administration procedure was used (57). The target BAC 
was 0.04% for moderate drinkers and 0.08% for binge drinkers. The amount of alcohol 
was calculated using the Matthews and Miller’s formula: BAC = [(The number of 
drinks/2) × (GC/Weight in pounds)] - (0.016×the number of hours over the consumed 
alcohol)] (58). In their formula, GC is a gender constant, 9.0 for women and 7.5 for men, 
and 0.016 is a constant for alcohol metabolism rate. Vodka (80 proof) and fruit juice (18g 
sugar/200ml) were mixed in a 1:3 ratio.  
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The participants were asked to drink a third of the drink relatively quickly and to 
finish the rest over a 30-minute period. If the level was below the target, an additional shot 
was given. Once the target BAC was reached, participants stayed in the laboratory until 
their BAC levels were down to 0.04. Participants were only allowed to leave the laboratory 
with a sober friend/family member or to use a cab. All participants were compensated with 
money for their participation. Abstainers received $20, $20, and $25 checks for the first, 
second and last study visit, respectively. Moderate and binge drinkers received $20, $30, 
and $50 checks for the first, second and last visit, respectively. Additionally, moderate and 
binge drinkers received $20 in cash on the second and third visit for transportation costs. 
After the QST on Visit 1 and Visit 3, participants were asked to report their guess about 
the study purpose. Most drinkers mentioned alcohol effects whereas abstainers did not 
mentioned alcohol. Consequently, the study hypothesis was blinded only to the abstainers. 
One male and four female experimenters conducted this experiment. One male and 
one female experimenter were involved in prescreening, tracking recruitment, obtaining 
informed consent, verifying compliance of study preparation (including breathalyzer test), 
and giving a reminder call for their appointment. Instruction for study preparation was the 
same as in the Experiment 1 except for instructions on alcohol consumption. Self-report 
and breathalyzer tests were used to assess their compliance of alcohol consumption. One 
participant whose baseline BAC was non-zero on the first study visit did not undergo the 
QST and the visit was rescheduled. Two female experimenters administered alcohol or 
juice on the second study visit. The last female experimenter who was blinded for 
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participants’ drinking pattern and performed blood draws and the QSTs in the Experiment 
1 performed all blood draw and QSTs for Experiment 2.  
6.3 Statistical Analysis 
A 2 (visit) by 3 (group) repeated measures MANOVA was used to examine 
changes in mechanical, heat, and pressure pain thresholds. Nonparametric analyses were 
conducted for non-normal data and any significant violation of assumption.  
Sample Size Calculation 
GPower 3.1.9 was used to calculate a priori sample size for MANOVA repeated 
measures. Large between subject effect size (f=0.5) with α of .05 Type 1 error, 80% power, 
and 0.6 correlation coefficient among repeated pain measures (59) were entered. The 
results indicated a minimum sample size was a total of 36 (n = 12 each). 
Missing Data 
No missing values were found in pain sensitivity, blood samples, and physiological 
data. All questionnaires were completed with the exception of one binge drinker who 
completed only half of the survey after the QST at Visit 1 and another binge drinker who 
did not completed the ACQ survey before the QST at Visit 3. Pairwise deletion was used. 
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7. RESULTS 
EXPERIMENT 2 
Table 4. Experiment 2 Demographics and drinking patterns 
 Abstainers 
Moderate 
drinkers 
Binge Drinkers   
 M(SD) M(SD) M(SD) F or U* p 
N 12 12 12   
(Male/Female) (5/7) (6/6) (6/6)   
Caucasian (n) 5 7 9   
Asian (n) 5 4 0   
Other (n) 2 1 3   
% Cigarette 
Current/ex-smoker 
0/0 17/20 0/33   
Age 23.8(1.7) 25.3(2.3) 22.8(2.6)   3.7* .036 
Typical drinks 
(weekday) 
Men 
- 
3.8(1.2) 8.5(4.8) 
 
14.5* 
 
< .001 
Women - 3.2(1.7) 11.0(5.5)   
Typical drinks 
(weekend) 
Men 
- 
2.8(1.2) 7.2(3.5) 
12.0* < .001 
Women - 2.7(1.4) 6.8(1.8)   
Heaviest drinks 
Men 
- 
3.8(1.2) 10.5(3.3) 
  1.0* < .001 
Women - 3.5(1.4) 11.3(5.0)   
Ages at first drink  - 19.8(2.7) 18.3(2.2) 45.0* .113 
Years of drink - 4.5(3.2) 3.8(4.4) 57.0* .379 
Frequency - 3.5(0.9) 4.0(0.9) 47.5* .133 
HSS - 3.7(2.2) 6.9(2.6) 10.9 .003 
Other ethnicity includes Latin American, African, and multi-racial. Acute drinking: 
alcohol consumption within 48 hours before the experiment; *:Mann-Whitney U test, 
HSS: Hangover Symptoms Scale. 
 
 
Participants’ demographic information and drinking patterns are summarized in 
Table 4. Each group consisted of 12 participants. The majority was Caucasian for the binge 
(75%) and moderate drinker groups (58.3%). Different from Experiment 1, none of the 
participants from the abstainer or binge drinker groups endorsed being a current smoker.  
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At prescreening, binge drinkers reported consuming greater amounts of alcohol 
during weekdays, weekends, and the heaviest drinking days compared to moderate 
drinkers (Table 4). The first age to drink alcohol, year of regular drinking, and frequency 
of alcohol use were not different between the two drinking groups. Finally, as expected, 
binge drinkers reported experiencing more hangover symptoms for the past 12 months. 
 
 
 
Table 5. Experiment 2 Psychological traits 
 
Abstainers Moderate drinkers Binge drinkers 
 M SD M SD M SD 
DASS-DEP 5.3 4.1 4.3 6.5 5.3 6.2 
DASS-ANX 4.3 4.6 4.7 5.5 2.0 2.3 
DASS-STR 11.8 9.1 5.8 5.7 6.2 5.7 
PSS 17.6 7.2 14.2 4.5 12.8 6.7 
BIS-Total* 4.0 0.1 4.1 0.1 4.0 0.2 
BIS-ATTEN* 2.7 0.2 2.7 0.3 2.7 0.3 
BIS-MOTOR* 3.0 0.1 3.1 0.1 3.0 0.2 
BIS-PLAN* 3.0 0.2 3.0 0.2 3.0 0.2 
UPPS-Total 113.9 5.0 114.9 5.1 116.6 3.1 
UPPS-Lack of 
Premeditation 
24.8 3.3 24.3 4.4 24.5 2.7 
UPSS-Urgency 31.7 3.9 33.2 3.4 33.4 2.0 
UPSS-
Sensation 
seeking 
31.4a 2.7 31.7a 3.7 34.5b 2.4 
UPSS-Lack of 
Perseverance 
26.0 3.5 25.8 2.9 24.2 2.3 
ZKPQ-ImpSS 7.9 4.1 10.2 3.8 11.4 3.3 
DASS (Depression Anxiety Stress Scales)-DEP: Depression, ANX: Anxiety, STR: Stress; 
PSS: Perceived Stress Scale; BIS (Barratt Impulsiveness Scale)-ATTEN: Inattention, 
MOTOR: Motor Restlessness, PLAN: Non-Planning; ACQ (Acute Craving 
Questionnaire-NOW)-COMP: Compulsivity; XPCT: Expectancy; PURP: Purposefulness; 
EMOT: Emotionality, UPPS (UPPS Impulsive Behavior Scale), ZKPQ-ImpSS: 
Zuckerman-Kuhlman Personality Questionnaire–Impulsive Sensation Seeking; 
superscripts of a, b and c indicate significant difference in post hoc analysis. * log 
transformed. 
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Different from Experiment 1, none of the participants from the abstainer or binge 
drinker groups endorsed being a current smoker. At prescreening, binge drinkers reported 
consuming greater amounts of alcohol during weekdays, weekends, and the heaviest 
drinking days compared to moderate drinkers (Table 4). The first age to drink alcohol, 
year of regular drinking, and frequency of alcohol use were not different between the two 
drinking groups. Finally, as expected, binge drinkers reported experiencing more 
hangover symptoms for the past 12 months.  
7.1 Psychological Traits 
Baseline psychological traits were compared between the groups. The Kruskal-
Wallis test showed no difference in DASS-depression, anxiety, and stress scores (ps > 
.149). PSS scores were also similar between the groups, F (2, 33) = 1.90, p = .166. Except 
for depressive symptoms, these results are consistent with Experiment 1. In Experiment 
1, binge drinkers reported more depressive symptoms than abstainers. This difference in 
Experiment 1 was caused by less depressed abstainers and not by more depressed binge 
drinkers in comparison with abstainers and binge drinkers in Experiment 2. However, the 
baseline psychological traits of the groups with same drinking pattern were not different 
between Experiment 1 and 2 (ps of independent t tests > .095). Consistent with Experiment 
1, BIS total and subscale scores were not significantly different between the groups, Fs 
(2, 32) < 0.54, ps > .591. UPPS-total and subscale scores also showed levels of impulsivity 
and specific dimensions of impulsivity were similar across the groups, Fs (2, 33) < 1.40, 
ps > .262 with one exception. The binge drinkers reported engaging in more sensation 
seeking behaviors than the abstainer and moderate drinker groups, F (2, 33) = 3.89, p = 
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.030. ZKPQ-ImpSS scores reflecting both impulsivity and sensation seeking personality 
showed a marginal difference, F (2, 32) = 2.51, p = 0.97. 
7.2 Baseline Psychological and Physiological Sates 
At baseline, psychological (Kruskal-Wallis tests χ2 < 4.05, ps > .132) and 
physiological states were not different between the groups, Table 6. The results of an 
ANOVA indicated no group difference in HR, sqrtSCL, and RR, F (2, 33), ps > .558. 
SCLs were similar between the groups even when adjusting for ethnicity (White = 1 vs 
other ethnicity = 0, p = .702). The Kruskal-Wallis test also indicated that SBP and DBP 
were not different between the groups (ps > .062).  
 
 
Table 6. Experiment 2 Baseline physiological and psychological states 
 Abstainers Moderate drinkers Binge drinkers 
Psychological State M SD M SD M SD 
STAI 9.3 3.2 8.4 1.6 7.5 1.9 
PANAS-PA 30.4 5.4 30.3 6.3 31.0 9.6 
PANAS-NA 12.9 2.9 11.4 2.5 11.8 2.8 
SAM-V 5.4 1.4 5.8 1.7 6.3 1.3 
SAM-A 2.6 2.0 3.6 1.9 3.0 2.2 
SAM-D 6.0 1.8 7.2 1.6 7.3 1.2 
Physiological State       
HR(beat/min) 72.0 10.1 71.7 10.8 73.4 8.5 
sqrtSCL(μS) 2.3 0.5 2.3 0.9 2.6 0.8 
RR(breath/min) 13.0 4.1 13.3 2.9 12.6 1.9 
SBP(mmHg)* 113.1 13.5 110.8 10.8 109.3 12.7 
DBP(mmHg)* 72.4 8.1 73.8 9.4 70.5 10.2 
STAI: State-Trait Anxiety Inventory-6, PANAS (Positive and Negative Affect Schedule)-
PA: Positive affect, NA- Negative affect, SAM (Self-Assessment Manikin)-V: Valence, 
A-Arousal, D: Dominance; HR: Heart Rate, SCL: Skin Conductance Level, RR: 
Respiration Rate; SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure;*: the 
Kruskal-Wallis test followed by the Mann-Whitney U. 
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7.3 Influence of Alcohol on Visit 3 
On Visit 3, all participants’ BACs were zero prior to pain testing. Alcohol’s 
stimulant and sedative effects were measured with the BAES and acute hangover 
symptoms were measured with the ACQ. About 12 hours after alcohol consumption 
(moderate drinkers to 0.04% and binge drinkers to 0.08%), reported stimulant and sedative 
effects of alcohol were similar between the moderate and the binge drinker groups (Mann-
Whitney U = 57 for the stimulant effect and 72 for the sedative effect, ps > .374). The 
means of the BAES-stimulant effect scores were 14.0 (SD = 20.0) for the moderate drinker 
group and 19.8 (SD = 21.2) for the binge drinker group. The means of the BAES-sedative 
effect scores were 10.8 (SD = 13.4) for the moderate drinker group and 11.6 (SD = 14.2) 
for the binge drinker group. Different from Experiment 1, AHS scores were not different 
between the moderate (M = 5.8, SD = 2.9) and binge drinker groups (M = 4.9, SD = 5.3). 
Mann-Whitney tests indicated that AHS scores were higher in binge drinkers with acute 
alcohol use in Experiment 1 than binge drinkers with acute alcohol use in Experiment 2. 
During the exit interview, 75% of binge drinkers reported the amount of alcohol consumed 
in the laboratory was less than their typical drinking and 25% reported about the same. 
Subsequently, all binge drinkers reported less hangover symptoms on Visit 3 than their 
typical morning after drinking.  
7.4 Pain Sensitivity 
First, peripheral pain sensitization was evaluated. A 2 (visit) by 3 (group) repeated 
measures MANOVA was conducted for mechanical (log transformed), heat, and pressure 
pain thresholds (log transformed), separately (Fig. 22). The results indicated no main 
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effect of visit (ps > .140), group (ps > .295), or interaction (ps > .241) with one exception. 
Time was significant for pressure pain threshold (Wilks’ Λ = .883, p = .044), suggesting 
that pressure pain was reduced by 14% at Visit 3. Although not significant, the moderate 
drinkers showed the most reduction (27%), followed by binge drinkers (15%) and 
abstainers (5%). In entering gender as a factor or covariate, the result remained unchanged. 
In comparison with Experiment 1 results, the results of mechanical and heat pain 
thresholds consistently showed no association with alcohol withdrawal, but failed to 
replicate the enhancement of pressure pain thresholds during alcohol withdrawal. 
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Fig. 22. Changes in mechanical, heat, and pressure pain threshold from Visit 1 to Visit 3. 
Error bars = SEM. 
 
 
 
Capsaicin-induced Spontaneous Pain 
Second, spontaneous pain intensity and unpleasantness were compared between 
the groups on Visit 1 and Visit 3. Because the data distributions were not normal and 
uncorrectable with transformation, the average and peak pain intensity were computed for 
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each visit and nonparametric analyses were conducted. The pain intensity and 
unpleasantness ratings reported every two minute are depicted in Fig. 23. 
 
 
Fig. 23. Average pain intensity and unpleasantness ratings every two minute on Visit 1 
and Visit 3. Error bars = SEM. 
 
 
 
Kruskal-Wallis tests were conducted to compare average capsaicin-induced pain 
on Visit 1 and changes on Visit 3 (Fig. 24). Neither pain intensity (p = .649) nor 
unpleasantness (p = .700) was different between the groups on Visit 1. There were also no 
group differences in changes in pain intensity (p = .669) or unpleasantness (p = .563) on 
Visit 3. However, changes in average pain intensity showed a trend toward increasing in 
binge drinkers.  
 68 
-1
0
1
2
3
4
V is it  1
P
a
in
 I
n
te
n
s
it
y
 (
0
-1
0
)
-1
0
1
2
3
4
V is it  3
P
a
in
 U
n
p
le
a
s
a
n
tn
e
s
s
 (
0
-1
0
)
A b s t a in e r s
M o d e r a t e  d r in k e r s
B in g e  d r in k e r s
-2
0
2
4
C h a n g e s  in  S p o n t a n e o u s  P a in  In t e s n t iy  a t  V is it  3

 P
a
in
 i
n
te
n
s
it
y
-2
0
2
4
C h a n g e s  in  S p o n t a n e o u s  P a in  U n p le a s a n tn e s s  a t  V is it  3

 P
a
in
 U
n
p
le
a
s
a
n
tn
e
s
s
 
Fig. 24. Scatter plots for each individual’s average capsaicin-induced pain intensity (top 
left) and unpleasantness (top right) on Visit 1 and change in pain intensity (bottom left) 
and unpleasantness (bottom right) on Visit 3. Mid-lines represent medians. 
 
 
 
Peak pain intensity and unpleasantness during capsaicin application were 
compared between the groups (Fig. 25). The results of Kruskal-Wallis tests indicated that 
neither peak pain intensity (p = .762) nor unpleasantness (p = .805) was different between 
the groups on Visit 1. Changes in pain intensity (p = .296) and unpleasantness (p = .732) 
on Visit 3 were also not different between the groups.  
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Fig. 25. Scatter plots for each individual’s peak pain intensity (top left) and unpleasantness 
(top right) during capsaicin application on Visit 1. Scatter plots for change in pain intensity 
(bottom left) and unpleasantness (bottom right) on Visit 3. Mid-lines represent medians 
 
 
 
Exploratory pattern analyses were conducted to examine whether the average 
number of drinks during the weekends, weekdays, and the heaviest drinking days for the 
past month predicted capsaicin-induced pain intensity and unpleasantness. The 
exploratory analyses found a significant result (Fig. 26). Up to a half-standard drink 
predicted a slight decrease in peak pain intensity during capsaicin application, but 
thereafter, more drinks predicted an increased in peak pain intensity.  
 70 
0 5 1 0 1 5
0
2
4
6
8
V is it  1
T h e  n u m b e r  o f  w e e k e n d  d r in k s
P
e
a
k
 p
a
in
 i
n
te
n
s
it
y
y  =  0 .1 X
2
-0 .3 X + 1 .4 , p  = .0 2 8 , r
2
=  .1 9
 
Fig. 26. Predicting capsaicin induced-peak pain intensity from the number of drinks during 
weekends 
 
 
 
Capsaicin-induced Flare 
On Visit 1, sizes of capsaicin-induced flare were not different between the groups 
(Kruskal-Wallis χ2 = 2.36, p = .308). Changes in flare size on Visit 3 were marginally 
different between the three groups (Kruskal-Wallis χ2 = 4.98, p = .083). Post-hoc Mann-
Whitney U tests indicated a significant difference between the moderate and binge drinker 
groups, (U = 36.0, p = .039), Fig. 27. On Visit 3, the flare size was increased in the binge 
drinker group (M = 1.3cm2, SD = 2.5) whereas the flare was decreased in the abstainers 
(M = -0.5cm2, SD = 2.1) and moderate drinkers groups (M = -1.4cm2, SD = 4.0). When 
comparing intensity of the flare, the results consistently showed no baseline difference (p 
= .566). However, changes in intensity on Visit 3 were marginally different between the 
groups (p = .089). Post-hoc Mann-Whitney U tests indicated a significant difference 
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between the moderate and binge drinker groups (U = 37.0, p = .045). On Visit 3, the flare 
intensity was increased in the binge drinker group (M = 332.3PU, SD = 486.3) whereas 
the flare was decreased in the moderate drinker group (M = -42.3PU, SD = 288.8). 
Abstainers showed a slight increase in flare intensity on Visit 3 (M = 10.0PU, SD = 297.4). 
 
 
0
2
4
6
B a s e lin e  F la r e
F
la
re
 (
c
m
2
)
-3
-2
-1
0
1
2
3
C h a n g e s  in  F la r e

  
F
la
re
 (
c
m
2
)
A b s t a in e r s
M o d e r a te  d r in k e r s
B in g e  d r in k e r s
*
Fig. 27. Comparison of flare size on Visit 1 and changes in flare size on Visit 3. Error bars 
= SEM. 
 
 
 
Area of Secondary Allodynia 
Secondary allodynia was compared between the groups. Before comparing 
secondary allodynia, baseline pain responses to mechanical stimuli (26gF) on the furthest 
(referencing) point were evaluated. The results of Kruskal-Wallis tests indicated no group 
differences on dominant and non-dominant feet (ps >.633). Participants reported the 
mechanical stimulation on the non-dominant foot was overall not painful on Visit 1 (M = 
0.5cm, SD = 0.5) and Visit 3 (M = 0.3cm, SD = 0.4). This was also true for the dominant 
foot on Visit 1 (M = 0.5cm, SD = 0.5) and Visit 3 (M = 0.4cm, SD = 0.4).  
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Areas of secondary allodynia were calculated in two ways. First, the areas were 
calculated with boundaries of any persistent increase in pain intensity from the furthest 
point on each spoke. On Visit 1, no significant difference in the area of secondary 
allodynia was found, Kruskal-Wallis χ2 = 2.45, p = .294. The means for the areas were 
32.6cm2 (SD = 22.5) for the abstainer group, 42.3cm2 (SD = 32.4) for the moderate drinker 
group, and 27.2cm2 (SD = 29.6) for the binge drinker group. An ANOVA was conducted 
to compare change scores of the area from D1 and D3 (normal distribution, Shapiro-Wilk 
= .98, p = .641). The result indicated no significant group difference, F (2, 33) = 0.58, p = 
.568, Fig. 28. On average, the areas remained unchanged (M = 0.5, SD = 23.2).  
 
 
 
Fig. 28. Graphical depiction of the areas of secondary allodynia on the capsaicin 
application site using two methods for Visit 1 and Visit 3 
 
 
 
Second, the areas were calculated with boundaries of any persistent increase in 
pain intensity from the baseline. Consistent with the results with the first method, the areas 
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on Visit 1 were not different between the groups, Kruskal-Wallis χ2 = 0.48, p = .787. The 
means for the areas were 23.0cm2 (SD = 18.0) for the abstainer group, 30.7cm2 (SD = 
27.7) for the moderate drinker group, and 24.9cm2 (SD = 27.5) for the binge drinker group. 
An ANOVA was conducted to compare the change scores of the area from D1 and D3 
(Shapiro-Wilk = .95, p = .072). The results indicated no significant group difference, F (2, 
33) = 0.50, p = .610, Fig. 29. However, when using this method, the mean of the areas 
increased to 8.3cm2 (SD = 19.8) on Visit 3. 
The second method assumes that pain sensitivity would not be the same across the 
foot surface. The results of the repeated measures MANOVA showed that pain ratings on 
the spoke 3 on Visit 1, Λ = 0.56, F (9, 27) = 2.40, p = .038, and the spoke 4 on Visit 3, Λ 
= 0.54, F (9, 27) = 2.59, p = .027, were significantly increased when it got closer to the 
center. Yet, pain ratings on the other spokes showed no significant changes (ps > .062), 
Fig. 29.  
Areas of secondary allodynia were also calculated on the non-capsaicin application 
site. The results were similar to the capsaicin application foot, Kruskal-Wallis χ2 = 1.65, 
p = .438. Notably, the areas of allodynia on non-capsaicin application sites were not zero 
on Visit 1, suggesting the occurrence of secondary allodynia on the contralateral side. The 
means for the areas were 19.5cm2 (SD = 19.5) for the abstainer group, 32.8cm2 (SD = 
34.7) for the moderate drinker group, and 20.6cm2 (SD = 31.2) for the binge drinker group. 
Changes in the area from D1 and D3 were compared between the groups and the results 
found no significant group difference (Kruskal-Wallis = 0.18, p = .915). On average, the 
areas remained unchanged or decreased slightly (M = -1.8, SD = 9.0) on Visit 3. 
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Fig. 29. Pain intensity ratings to 26g von Frey on non-dominant foot before capsaicin 
application 
 
 
 
In examining areas on the unaffected site with the second method, the areas on 
Visit 1 were not different between the groups, Kruskal-Wallis χ2 = 0.80, p = .670. The 
means for the areas were 9.7cm2 (SD = 6.9) for the abstainer group, 18.0cm2 (SD = 20.7) 
for the moderate drinker group, and 15.2cm2 (SD = 24.5) for the binge drinker group. An 
ANOVA was conducted to compare the change scores of the area from D1 and D3 
(Shapiro-Wilk = .95, p = .072). The results indicated no significant group difference (p = 
* 
* 
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.831). Using this method, the mean of the areas decreased to 4.2cm2 (SD = 18.2) on Visit 
3. 
Primary Allodynia 
Changes in mechanical pain thresholds on the capsaicin application sites and the 
vehicle sites were compared between the groups. The results of an ANOVA indicated that 
changes in mechanical pain thresholds on Visit 1 and Visit 3 did not differ between the 
groups (ps > .093). On average, mechanical pain thresholds were reduced by 19% on the 
capsaicin application site on both Visit 1 and Visit 3. In contrast, the thresholds were 
increased by 4% and 1% on the vehicle sites on Visit 1 and Visit 3, respectively.  
7.5 The Role of Stress Hormones in Pain Sensitivity 
For the group comparison with epinephrine levels, the results of a 2 (visit) by 2 
(pre and post pain testing within visits) by 3 (group) repeated measures MANOVA 
indicated no significant main effect of visits (p = .650) and pain testing (p = .325) and no 
significant interactions (ps > .503), Fig. 30. The non-significant group by visit interaction 
indicated that alcohol withdrawal did not increase epinephrine levels. To note, the visit by 
pain testing interaction was marginally significant, Λ = .603, F (1, 33) = 3.56, p = .068. 
Pain testing increased the average epinephrine levels from 8.6 (SD = 3.0) to 9.4 (SD = 2.9) 
on Visit 1 whereas pain testing decreased the levels from 9.2 (SD = 2.7) to 9.1 (SD = 2.2) 
on Visit 3. There was a main effect of group, F (2, 33) = 5.24, p = .011, partial η2 = .241. 
LSD post hoc tests indicated that the epinephrine levels were lower in the moderate drinker 
group than the binge drinker (p = .006) and abstainer groups (p = .012). The levels were 
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not different between the binge drinker and abstainer groups (p = .806), Fig. 30, bottom. 
The findings of elevated overall epinephrine levels in the binge drinker group compared 
to the abstainer or moderate drinker groups are consistent with Experiment 1. However, 
the elevated basal epinephrine did not alter pain sensitivity in binge drinkers at baseline 
or during alcohol withdrawal because pain sensitivity was not different at baseline and did 
not change pain sensitivity during alcohol withdrawal.  
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Fig. 30. Changes in epinephrine levels before and after pain testing on Visit 1 (top left) 
and Visit 3 (top right), and comparison of overall epinephrine levels between the groups 
(bottom), Error bars = SEM. 
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Fig. 31. Changes in cortisol levels before and after pain testing on Visit 1 (top left) and 
Visit 3 (top right), and comparison of overall cortisol levels between the groups 
(bottom), Error bars = SEM. 
 
 
 
For the group comparison with cortisol levels, the results of a 2 (visit) by 2 (pre 
and post pain testing within visits) by 3 (group) repeated measures MANOVA indicated 
a main effect of visit, Λ = .822, F (1, 33) = 7.13, p = .012, and pain testing, Λ = .233, F 
(1, 33) = 108.47, p < .001, Fig. 31. Overall, cortisol levels increased from 10.0 (SD =1.6) 
on Visit 1 to 10.4 (SD =1.6) on Visit 3. However, there was no significant group by visit 
interaction (p = .200), suggesting that alcohol withdrawal did not increase cortisol levels. 
Additionally, pain testing did not increase the cortisol levels. The average cortisol levels 
decreased from 11.4 (SD = 1.9) to 8.9 (SD = 1.6). All the other results were not 
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significant (ps > .177). These findings of no significant group difference and decreases 
in cortisol after pain testing are consistent with Experiment 1. 
7.6 The Role of Negative Affect in Pain Sensitivity 
The results of Kruskal-Wallis tests indicated that changes in anxiety after pain 
testing were not significantly different between the groups on Visit 1 (χ2 = 0.10, p = .950) 
and Visit 3 (χ2 = 0.80, p = .671). Anxiety levels on average increased after pain testing on 
Visit 1 (M = 1.1, SD = 2.1) and decreased on Visit 3 (M = -0.4, SD = 3.7). Changes in 
baseline anxiety levels from Visit 1 to Visit 3 were not different between the groups, χ2 = 
1.56, p = .458. This suggests that anxiety levels were not higher in the morning after binge 
drinking compared to the morning after no alcohol or moderate amount of alcohol 
consumption.  
Spearman rho correlations were computed to examine whether the binge drinkers’ 
state anxiety at baseline were related to all pain sensitivity indices at Visit 1. The results 
indicated no significant relationships (ps > .170) except a marginal relationship between 
state anxiety and capsaicin-induced pain unpleasantness in the abstainer group (r = .50, p 
= .064). On Visit 1, changes in anxiety levels and pain sensitivity were also unrelated in 
all groups (ps > .266). However, higher levels of capsaicin-induced pain intensity (r = .61, 
p = .037) and unpleasantness (r = .61, p = .036) were associated with greater increases in 
anxiety in the moderate drinker group on Visit 3.  
Next, Spearman rho correlations were computed to examine whether changes in 
baseline state anxiety on Visit 3 from Visit 1 would be related to pain sensitivity. The 
results indicated more induced anxiety was associated with increased heat pain thresholds 
 79 
in the binge drinker group on Visit 3 (r = .62, p = .033), suggesting that alcohol 
withdrawal-induced anxiety would have a hypoalgesic effect. Additionally, more induced 
baseline anxiety on Visit 3 showed a trend towards less capsaicin induced pain intensity 
(r = -.53, p = .065), and unpleasantness in the abstainer groups (r = -.56, p = .076). No 
other relationships were significant across the other groups (ps > .105).  
In sum, binge drinking did not increase the level of state anxiety the morning after 
drinking. Unexpectedly, higher levels of withdrawal induced anxiety were associated with 
reduced heat pain sensitivity in the binge drinker group and greater capsaicin-induced 
spontaneous pain was associated with more induction of anxiety the morning after 
drinking moderate amounts of alcohol.  
7.7 Psychological Responses to Pain Testing 
First, changes in SAM-valence scores were compared between the groups on 
Visit 1 (Fig. 32, top left) and Visit 3 (Fig. 32, top right). The result of a 5 (time) by 3 
(group) repeated measures ANOVA showed a significant change over time, F (4, 109) = 
5.20, p = .002, Greenhouse-Geisser ε = .66, without significant interaction (p = .430). A 
linear function best fit the data, suggesting that unpleasant emotion decreased over time, 
F (1, 33) = 12.22, p = .001. Additionally, the main effect of group was significant, F (1, 
33) = 5.60, p = .008. The results of post hoc LSD indicated that the moderate (M = 6.8, 
SD = 1.3) and binge drinker groups (M = 6.8, SD = 1.3) showed higher levels of 
unpleasantness than the abstainer group (M = 5.2, SD = 1.3, ps < .007). 
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Fig. 32. Changes in the SAM-valence, arousal, and dominance in response to pain tests 
on Visit 1 (left) and Visit 3 (right), Error bars = SEM. 
 
 
In conducting 5 (time) by 3 (group) repeated measures ANOVAs for all the others, 
time was a significant main effect for the SAM-arousal on Visit 1 (p < .005), but not for 
the SAM-arousal on Visit 3 (p = .218) and SAM-dominance on Visit 1 (p = .127) and Visit 
3 (p = .841). A cubic function best fit the data, F(1, 33) = 17.01, p < .001, suggesting that 
levels of perceived arousal were increased up to heat pain threshold testing, decreased 
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after pressure pain thresholds and capsaicin application, and then slightly increased after 
the last mechanical pain threshold test (Fig. 32, middle left). In contrast, perceived arousal 
did not change over repeated pain tests on Visit 3 (Fig. 32, middle right). Consistent with 
Experiment 1, perceived dominance remained unchanged over time on Visit 1 (Fig. 32, 
bottom left) and Visit 3 (Fig. 32, bottom right). 
7.8 Physiological Responses to Pain Testing 
For HRs, the results of a 2 (visit) by 2 (pre and post pain testing within visits) by 
3 (group) repeated measures MANOVA indicated a significant main effect of pain testing, 
Λ = .41, F (2, 31) = 22.77, p < .001, Fig. 33, top. A linear function best fit the data, 
suggesting overall decrease in HR over time, F (1, 32) = 24.4, p < .001. There were no 
other significant main or interaction effects (ps > .052), suggesting no alcohol withdrawal 
induced changes in HR. 
The results of a 2 (visit) by 2 (pre and post pain testing within visits) by 3 (group) 
repeated measures MANOVA with SCLs indicated a significant main effect of pain 
testing, Λ = .16, F (2, 32) = 83.17, p < .001, Fig. 33, middle. A quadratic function best fit 
the data, suggesting an increase in SCL during pain testing and then a decrease afterwards, 
F (1, 32) = 169.6, p < .001. There were no other significant main or interaction effects, ps 
> .082, suggesting no alcohol withdrawal-induced changes in SCL. Additionally, the 
results of a repeated measures MANOVA showed no difference for SCRs to mechanical, 
heat, and pressure pain thresholds (ps >.190). 
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Fig. 33. Changes in HR, SCL, and RR before, during, and after pain testing on Visit 1 
and Visit 3 
 
 
 
The results of a 2 (visit) by 2 (pre and post pain testing within visits) by 3 (group) 
repeated measures MANOVA with RRs indicated significant main effects of visit, Λ = 
.65, F (1, 32) = 17.1, p < .001 and pain testing, Λ = .71, F (2, 31) = 6.31, p = .005. In 
addition, a visit by pain testing interaction was significant, Λ = .81, F (2, 31) = 3.75, p 
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=.035. On Visit 1, RRs were elevated during pain testing (M = 14.3, SD = 1.8), then 
decreased afterwards (M = 13.4, SD = 2.5) compared to baseline (M = 13.0, SD = 3.1). On 
Visit 3, RR were elevated before (M = 14.7, SD = 2.6) and during pain testing (M = 14.6, 
SD = 2.2), then decreased (M = 13.9, SD = 2.9). No other significant main or interaction 
effects were found, ps > .272, suggesting no alcohol withdrawal induced changes in RR. 
Two 2 (visit) by 2 (pre and post pain testing within visits) by 3 (group) repeated 
MANOVA were conducted for SBP and DBP. The results indicated no significant main 
or interaction effects for SBP, ps > .054, but a main effect of pain testing for DBP, Λ = 
.62, F (1, 33) = 20.0, p < .001. DBP was on average increased from 71.9mmHg to 
75.9mmHg after pain testing. The non-significant interactions with group suggested 
alcohol withdrawal did not influence SBP and DBP. 
7.9 The Role of Alcohol Withdrawal and Pain in Alcohol Craving 
Kruskal-Wallis tests were conducted to compare baseline craving on Visit 1 (Fig. 
34). The total ACQ scores were significantly different between the groups, χ2 = 8.9, p = 
.012. Consistent with Experiment 1’s findings, the results of post-hoc Mann-Whitney tests 
showed that the moderate (U = 32.0, p = .020) and binge drinkers (U = 25.5, p = .006) 
reported greater alcohol craving than the abstainers. Alcohol craving was not different 
between moderate and binge drinkers (U = 60.0, p = .514). The baseline ACQ subscale 
scores were also compared. The results of Kruskal-Wallis tests indicated group difference 
in ACQ-XPCT scores (χ2 = 10.0, p = .007) and marginal difference in ACQ-PURP (χ2 = 
6.0, p = .051), but no differences for the others (ps > .085). The results of post-hoc Mann-
Whitney tests indicated that the moderate (p = .033) and binge drinkers (p = .003) reported 
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having greater positive expectancy about alcohol than abstainers, but only binge drinkers 
reported having stronger urges to drink with actual intent and planning to drink (p = .024). 
Changes in the total and subscale ACQ scores from Visit 1 to Visit 3 were 
compared between the groups (Fig. 34). The results of Kruskal-Wallis tests showed no 
significant group difference (ps >.100). Consequently, alcohol withdrawal did not enhance 
craving in young adult binge drinkers. When comparing changes in the total and subscale 
ACQ scores before and after pain testing, no significant group difference was found on 
Visit 1 (ps > .186) or Visit 3 (ps > .404). In sum, pain did not increase alcohol craving in 
young adult binge drinkers regardless of the acute alcohol use episode.  
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Fig. 34. Changes in ACQ scores before and after pain testing on Visit 1 and Visit 3 
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8. DISCUSSION 
This experiment had four objectives. The first objective was to determine whether 
alcohol withdrawal-induced hyperalgesia would occur in young adult binge drinkers. The 
second objective was to examine whether stress hormones (i.e., epinephrine and cortisol) 
would be associated with alcohol withdrawal induced hyperalgesia. Third, the current 
study examined whether negative affect during alcohol withdrawal would enhance 
withdrawal-induced hyperalgesia. The last objective was to examine whether alcohol 
withdrawal and pain would enhance alcohol craving. It was hypothesized that binge 
drinkers would show pain hypersensitivity during acute alcohol withdrawal, plasma 
epinephrine and cortisol would be increased in binge drinkers and their levels would be 
further elevated during alcohol withdrawal, higher levels of negative affect during alcohol 
withdrawal would enhance alcohol withdrawal-induced hyperalgesia, and lastly, pain 
during alcohol withdrawal would increase craving.  
Experiment 1 was conducted to test these hypotheses with a cross-sectional design 
focusing on peripheral pain sensitivity. Experiment 2 was a within-subject design testing 
both peripheral and central pain sensitivity. Experiment 1 showed that sensitivity to 
pressure pain was associated with binge drinking. Binge drinkers showed a slight decrease 
in pressure pain threshold and moderate drinkers showed a slight increase in pressure pain 
threshold. After drinking, binge drinkers’ pressure pain thresholds were further decreased. 
Sensitivity to cutaneous mechanical and heat pain did not altered by binge drinking. 
Experiment 2 consistently showed that binge drinkers’ cutaneous mechanical and heat 
pain thresholds were similar to abstainers’ and moderate drinkers’, but it failed to replicate 
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pressure pain threshold results. Capsaicin induced spontaneous pain intensity and 
unpleasantness were not different between the groups. However, exploratory pattern 
analysis showed a J-shape relationship between peak pain intensity and the number of 
drinks on the weekend. Additionally, the size and intensity of capsaicin-induced flare were 
increased on the morning after binge drinking. Lastly, areas of secondary allodynia were 
not different between the groups. Therefore, binge drinking and acute alcohol withdrawal 
did not alter central pain sensitivity. For the second hypothesis, Experiment 1 and 2 both 
showed elevated epinephrine levels in the binge drinkers compared to the moderate 
drinkers, but the levels were not further elevated by acute alcohol withdrawal after binge 
drinking. Both experiments also consistently showed that cortisol levels were unrelated to 
binge drinking. Different from the third hypothesis, Experiment 1 found that greater state 
anxiety at baseline was associated with lower pressure pain thresholds only in abstainers. 
Experiment 2 unexpectedly found that binge drinkers’ state anxiety and heat pain 
threshold were positively correlated on the morning after drinking; therefore, more anxiety 
during alcohol withdrawal was associated with a hypoalgesic effect. Consequently, 
Experiments 1 and 2 showed that negative affect during alcohol withdrawal did not 
moderate alcohol withdrawal-induced hypersensitivity to pain. Experiment 1 showed 
greater alcohol craving in moderate and binge drinkers compared to abstainers. However, 
levels of craving were similar between moderate and binge drinkers. Specifically, this 
difference was seen in positive alcohol expectancy and having strong intent and making 
plans for drinking. Experiment 2 demonstrated that this elevated craving was not further 
enhanced by alcohol withdrawal and pain. Both moderate and binge drinkers consistently 
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showed higher levels of positive alcohol expectancy than the abstainers in Experiment 2, 
but different from Experiment 1, strong urges to drink with actual intent and plans were 
specific to binge drinkers.  
Caveats of Evaluating Pain Sensitivity in Experiment 1 and Experiment 2 
Before going over the findings from Experiment 1 and Experiment 2, 
understanding differences between the two experimental designs are important. 
Experiment 1 evaluated pain sensitivity during alcohol withdrawal after naturalistic 
drinking, but depended on their self-report and recall of recent drinking episode. 
Experiment 2 compared pain sensitivity before and after consumed alcohol up to a BAC 
of 0.08%, the NIAAA’s definition of binge drinking. Although Experiment 2 intended to 
assess alcohol withdrawal-induced hyperalgesia in a controlled setting, a BAC of 0.08% 
seemed to be below the most binge drinker’s typical drinking. Consequently, most binge 
drinkers in Experiment 2 reported less severe hangover symptoms after laboratory alcohol 
administration than their typical morning after drinking and their hangover symptoms 
were less severe than binge drinkers with acute alcohol consumption in Experiment 1. 
Additionally, the study hypothesis was blinded to all participants in Experiment 1, but it 
was only blinded to abstainers in Experiment 2. These caveats should be kept in mind 
during the following discussion. 
Hypersensitivity to Muscle Pain during Alcohol Withdrawal 
In Experiment 1, binge drinkers showed a lower muscle pressure pain threshold, 
which was reduced further during alcohol withdrawal. However, cutaneous mechanical 
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and heat pain thresholds were not changed. These results suggest that alcohol withdrawal 
might induce hypersensitivity to muscle pressure pain, but would not affect cutaneous 
mechanical and heat pain sensitivity in the early stages of binge drinking. Notably, this 
effect size was large (η2 = .14). This is consistent with animal results showing reduced 
pressure pain threshold during alcohol withdrawal (6,17,18), but inconsistent in that 
animal results also show reduced mechanical and heat pain thresholds during alcohol 
withdrawal (8,18,60). Muscle pain can be observed in neuropathy (61) and muscle ache is 
a common hangover symptom (62). Known causes for alcoholic neuropathy are nutritional 
deficiency (e.g., thiamine), alcohol’s neurotoxicity, or its metabolites (i.e., acetaldehyde) 
(63). However, the pathogenesis is less defined for alcohol withdrawal-induced 
hypersensitivity to muscle pain.  
Animal studies have found that the SAM (e.g., epinephrine) and HPA (e.g., 
cortisol) stress axes play a critical role in alcohol withdrawal-induced muscle hyperalgesia 
(17). Animal research indicates that epinephrine and cortisol fully mediate the 
development and maintenance of alcohol withdrawal-induced hyperalgesia (17). The 
current study demonstrated that some of these animal findings can be translated into 
humans - epinephrine was elevated in binge drinkers, but alcohol withdrawal did not 
further increase epinephrine levels. Although additional pharmacological research is 
needed to determine whether epinephrine mediates withdrawal-induced hyperalgesia in 
humans (e.g., using β-adrenergic antagonist), the current results suggest that basal 
epinephrine levels alone explain a small portion (7%) of alcohol withdrawal induced 
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hyperalgesia. Different from the animal findings, the current study did not find any 
changes in cortisol.  
According to the animal findings, alcohol withdrawal in the early stages of alcohol 
intoxication activates both the SAM and HPA axes and is involved in the induction and 
maintenance of alcohol withdrawal-induced hyperalgesia with a continued ethanol binge 
diet (17). Alcohol-withdrawal induced hyperalgesia was observed even at 1 week after 
cessation of the ethanol binge diet, but the role of epinephrine was not examined for this 
extended period of abstinence (17). In an animal study investigating the development and 
maintenance of stress-induced hyperalgesia, activation of both the SAM and HPA axes 
are necessary for the induction (64), but the SAM (epinephrine) axis is found to play a key 
role in its maintenance up to 2 weeks after exposure to stress (65). Therefore, persistent 
elevation of epinephrine levels after several years of binge drinking may be critical in the 
maintenance phase of alcohol withdrawal-induced hyperalgesia.  
Over time, repeated episodes of alcohol withdrawal and activation of stress axes 
may cause hyperalgesia. Therefore, the long-term changes in the dynamics of binge 
drinking and the stress adaptation process may explain the progressive changes in pain 
sensitivity. Our brain and body’s adaptive systems respond to stressful events such as 
alcohol withdrawal. Elevated epinephrine and cortisol responses during the initial 
episodes of alcohol intoxication and withdrawal are adaptive responses that work together 
with the other adaptive systems (e.g., the nervous, endocrine, immune systems) to regain 
the baseline stability (homeostasis) (66). Binge drinking in combination with other 
psychological and physical stressors, activate centrally organized adaptive systems to 
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maintain stability through changes (allostasis). After undergoing multiple stress 
challenges (allostatic load and repeated cycles of intoxication and withdrawal), these 
stress adaptive systems become dysregulated, and the dysregulated responses can be either 
“persistent” or “inadequate” (67). Human participants in the current study showed a 
“persistent” elevation of epinephrine after 2-4 years of drinking, while their epinephrine 
and cortisol responses were blunted during acute alcohol withdrawal. Therefore, the 
responses of the SAM and HPA stress systems may become “inadequate” during acute 
alcohol withdrawal. The current study did not find changes in basal cortisol levels in binge 
drinkers. Perhaps, binge drinkers’ relatively normal basal cortisol levels and their 
unresponsiveness to the binge drinking episode represent a form of allostatic load, 
whereby the HPA system becomes “inadequate” while the SAM system exhibits a 
persistent up regulation in responses to the physical stress of repeated episodes of alcohol 
intoxication and withdrawal. Here stress hormones were discussed as a potential 
mechanism involved in alcohol withdrawal-induced neuropathic pain because alcohol is 
believed to cause neuropathic pain. However, muscle damage (necrosis) from alcohol 
intoxication may induce or partially contribute to this hyperalgesia because muscle 
necrosis occurs in acute and chronic alcohol-induced myopathy that manifests with muscle 
pain (68,69). 
The binge drinkers in Experiment 1 and 2 were non-clinical healthy young adults 
with a relatively short history of drinking (i.e., about 2 years in Experiment 1 and 4 years 
in Experiment 2). Therefore, hypersensitivity to pressure pain may occur in advance of 
the development of clinical neuropathic pain. Clinically, this finding suggests that clinical 
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neuropathic pain may begin with further worsening pressure pain sensitivity or 
development of hypersensitivity to cutaneous mechanical and heat pain, reflecting sensory 
neuropathic pain. Additionally, the current experiment found that not all binge drinkers 
showed hypersensitivity to pressure pain. Similarly, previous studies report that alcoholic 
neuropathy develops in up to 49% of chronic alcoholics (3). Therefore, those who show 
hypersensitivity to muscle pain even in the early stages of binge drinking may be 
vulnerable to alcoholic neuropathic pain with prolonged binge drinking. A prospective 
study is needed to examine this possibility. 
Capsaicin-induced Pain and Flare during Alcohol Withdrawal 
In Experiment 2, capsaicin-induced spontaneous pain did not differ between the 
groups. However, exploratory pattern analyses found a J-shape curve relationship between 
the number of weekend drinks and peak pain intensity during capsaicin application. About 
a half drink was associated with slight reduction in peak pain intensity. Indeed, this pattern 
was also found in Experiment 1 with pressure pain thresholds. Moderate drinkers showed 
an increase in pressure pain thresholds whereas binge drinkers showed a decrease. This J-
shape curve has been reported in cardiovascular health, stroke, type II diabetes, and all-
cause mortality (70,71,72,73). Consequently, small amount of alcohol may have some 
analgesic effect against inflammatory-mediated pain and muscle pain.  
Although capsaicin-induced pain intensity did not differ between the groups, size 
and intensity of capsaicin-induced flare were increased after binge drinking. 
Consequently, alcohol withdrawal may induce the release of the proinflammatory 
cytokines, (e.g., interleukin-6). Because elevated interleukin-6 levels can induce persistent 
 92 
muscle hyperalgesia (74), Interleukin-6 mediated-persistent hyperalgesia in alcoholic 
neuropathy may be possible. Yet, the early stages of binge drinkers in the current study 
showed temporal enhancement of flare responses during alcohol withdrawal, but showed 
no persistent changes in the absence of binge drinking for at least three days.  
Central Sensitization during Alcohol Withdrawal 
Theoretically, alcohol withdrawal can alter central pain processing because CNS 
hyperexcitability is one of the alcohol withdrawal symptoms. However, CNS 
hyperexcitability is uncommon in the early stages of binge drinking. This might be a 
reason for the absence of a group difference in capsaicin-induce allodynia in the current 
study. Additionally, less hangover symptoms from laboratory alcohol administration 
might contribute to the null results. Consequently, a future study should examine whether 
central pain sensitization would emerge in long-term alcohol abusers without neuropathy.  
The Role of Negative Affect in Alcohol Withdrawal-induced Hyperalgesia 
Elevated levels of irritability, anxiety, and dysphoria are common symptoms of 
alcohol withdrawal. The current study measured the levels of state anxiety before and after 
a period of alcohol withdrawal as well as before and after pain testing. The binge drinkers 
in the current study showed no difference in state anxiety at the baseline, and in response 
to alcohol withdrawal and to laboratory pain testing. Additionally, anxiety-associated 
hyperalgesia to muscle pain was observed only in the abstainer group in Experiment 1. 
Unexpectedly, individual difference in alcohol withdrawal-induced anxiety was positively 
associated with cutaneous heat pain thresholds in the binge drinker group in Experiment 
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2. More increased anxiety during alcohol withdrawal was related to higher heat pain 
thresholds. In sum, negative affect did not exacerbate, but rather dampened withdrawal-
induced hyperalgesia.  
Issues in Translating Animal Findings to Humans 
Some of our findings in humans are consistent with findings from previous animal 
models of binge drinking. Notably, withdrawal-induced muscle hyperalgesia occurred 
even in the early stages of binge drinking in humans, but cutaneous mechanical and heat 
pain as well as central pain processing remained unaffected by binge drinking. 
Additionally, binge drinkers’ basal epinephrine levels were elevated, but levels did not 
increase any further during alcohol withdrawal. Cortisol levels were not altered by binge 
drinking. Animal protocols of ethanol binge diets administer alcohol to rats more regularly 
and frequently (4 days on and 3 days off) for up to 4 weeks (6,17) and the protocols 
assessing withdrawal-induced hyperalgesia evaluate pain sensitivity after stopping 10 
days of the continuous ethanol diet (8,60). Hence, animal studies demonstrate alcohol 
withdrawal-induced hyperalgesia in the early stages of a rigorous binge or excessive 
ethanol diet and this may reflect the mechanisms of induction. Additionally, animals were 
tested under homogenous conditions. For example, laboratory animals have the same 
genetic makeup, controlled diet, no other health risk factors, and a controlled environment. 
In contrast, human participants have large variability in drinking patterns and other related 
physiological, psychological, genetic, and environmental factors. Human subjects in the 
current study reported that the frequency of binge drinking was about 2 to 4 times a month 
and the period of drinking was 2 to 4 years. Thus, our human subjects had more binge-
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withdrawal cycles than used in the animal models, and the amount of alcohol consumed 
during each binge is likely to vary considerably between individuals. Clearly, the young 
adult binge drinkers in the current study were tested after a much longer period of alcohol 
use and patterns of drinking are likely to vary considerably between individuals. 
Additionally, several contributing factors co-exist in human binge drinkers and covary 
with alcohol use. For example, personality (i.e., sensation-seeking tendency), 
psychological conditions (i.e., depression), health risk behaviors (smoking, other 
substance use), life stressors, and coping (substance use as a coping strategy) may also 
affect alcohol abuse and pain sensitivity. Consequently, these multilevel and multi-system 
factors should be considered when attempting to understanding the mechanisms of alcohol 
withdrawal-induced hyperalgesia in humans. 
Pain and Craving 
Alcohol produces acute analgesic and delayed onset hyperalgesic effects. This 
time-dependent opposing process suggests a possibility of pain as being a motivation for 
drinking despite the fact that alcohol progressively worsens pain with persistent use (21). 
The current experiment indirectly examined this possibility by measuring changes in 
alcohol craving during withdrawal and after laboratory pain testing. The current study 
found that elevated alcohol craving was characteristics of both moderate and binge 
drinkers, but was unaffected by alcohol withdrawal and pain in the young adult binge 
drinkers. This null finding may be due to the nature of the laboratory pain, which is 
relatively brief, temporary, and less intense than clinical pain, which is often persistent, 
uncontrollable, and severe. Alternatively, the alcohol dose administered in the laboratory 
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may be insufficient to induce withdrawal symptoms and consequent craving. Importantly, 
the current results do not rule out the possibility that alcohol withdrawal and pain can 
motivate drinking to directly reduce negative affect and pain during alcohol withdrawal. 
However, the current findings suggest that these negative reinforcing properties of alcohol 
may not accompany changes in craving.  
Clinical Implications 
The current study demonstrated that hypersensitivity to muscle pain and more 
intense inflammatory-mediated pain during alcohol withdrawal occurred even in young 
adult binge drinkers who were otherwise healthy. This information can be delivered to all 
drinkers as a health warning. Additionally, elevated epinephrine levels in binge drinkers 
suggest that stress management may benefit binge and heavy drinkers by lowering the risk 
of stress related health problems. Lastly, QST, especially for pressure pain threshold, may 
be useful to identify individual with subclinical and early stages of alcoholic neuropathy 
or to prescreen vulnerable individuals for neuropathy. 
Limitations and Future Studies 
Experiment 1 compared pain sensitivity between the groups after naturally 
occurring drinking episodes. Consequently, this experiment was unable to recruit the 
target number of participants with acute alcohol use. Additionally, the abstainer and 
moderate drinker groups included an equal number of men and women whereas the group 
of binge drinkers without acute alcohol included more women and binge drinkers with 
acute alcohol use included more men. Future research should examine potential gender 
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differences in alcohol withdrawal-induced hyperalgesia. Lastly, this between subject-
design was limited in examining the direct effect of alcohol withdrawal on pain sensitivity 
because of unknown individual pain sensitivity at baseline. 
The critical limitation of Experiment 2 was the alcohol administration protocol 
because it failed to induce withdrawal symptoms the morning after binge drinking that 
were comparable to the individuals’ typical withdrawal symptoms. This suggests that 
laboratory alcohol administration targeting a BAC of 0.08% may be insufficient for 
investigating this withdrawal effect in binge drinkers. Additionally, some moderate and 
binge drinkers anticipated analgesic effects of alcohol. This preconception by some 
subjects of an analgesic effect may have influenced the QST results. 
Conclusion 
The current experiment demonstrated that alcohol withdrawal-hypersensitivity to 
muscle pain occurred in young adult binge drinkers with a relatively short history of 
drinking. Additionally, elevated basal levels of epinephrine were observed in binge 
drinkers, but levels did not change during alcohol withdrawal. Basal epinephrine 
contributed to withdrawal-induced hyperalgesia to a small degree, but cortisol did not play 
a role. The role of anxiety was minimal or associated with hypoalgesia during alcohol 
withdrawal. Finally, laboratory pain and alcohol withdrawal did not increase alcohol 
craving. Instead, elevated alcohol craving was a characteristic of young adult drinkers 
compared to abstainers.  
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